

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## The development and testing of an opioid tapering self-management intervention for long term pain – I-WOTCH

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053725
Article Type:	Original research
Date Submitted by the Author:	21-May-2021
Complete List of Authors:	<p>Sandhu, Harbinder; University of Warwick Warwick Medical School, Clinical Trials Unit</p> <p>Shaw, Jane; James Cook University Hospital</p> <p>Carnes, Dawn; Queen Mary University of London Barts and The London School of Medicine and Dentistry, Institute of Population Health Sciences</p> <p>Furlan, Andrea; Toronto Rehabilitation Institute; University of Toronto Faculty of Medicine</p> <p>Tysall, Colin; University of Warwick, UNTRAP; Coventry University, SUCE</p> <p>Adjei, Henry; University of Warwick Warwick Medical School, Warwick Clinical Trials Unit</p> <p>Muthiah, Chockalingam; University of Warwick, Warwick Clinical Trials Unit</p> <p>Noyes, Jennifer; James Cook University Hospital, Department of Pain Medicine</p> <p>Tang, Nicole; University of Warwick, Psychology</p> <p>Taylor, Stephanie; Queen Mary University of London Barts and The London School of Medicine and Dentistry, Institute of Population Health Sciences</p> <p>Underwood, Martin; University of Warwick Warwick Medical School, Warwick Clinical Trials Unit</p> <p>Willis, Adrian; University of Warwick, Warwick Clinical Trials Unit</p> <p>Eldabe, Sam; James Cook University Hospital, Department of Pain Medicine</p>
Keywords:	Pain management < ANAESTHETICS, Rehabilitation medicine < INTERNAL MEDICINE, MEDICAL EDUCATION & TRAINING, PAIN MANAGEMENT, PRIMARY CARE, Clinical trials < THERAPEUTICS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 The development and testing of an opioid tapering self-management  
4  
5  
6 intervention for long term pain – I-WOTCH  
7

8 Harbinder Kaur Sandhu, Jane Shaw, Dawn Carnes, Andrea Dompieri Furlan, Colin Bernard  
9  
10 Tysall, Henry Adjei, Chockalingam Muthiah, Jennifer Noyes, Nicole K Y Tang , Stephanie  
11  
12 JC Taylor, Martin Underwood, Adrian Willis, Sam Eldabe, On behalf of the I-WOTCH Team  
13  
14  
15

16  
17  
18 Harbinder Kaur Sandhu, Warwick Clinical Trials Unit, Warwick Medical School, University  
19  
20 of Warwick, Coventry CV4 7AL, UK  
21

22  
23 [Harbinder.K.Sandhu@warwick.ac.uk](mailto:Harbinder.K.Sandhu@warwick.ac.uk)  
24  
25

26  
27  
28 Jane Shaw, The James Cook University Hospital, Middlesbrough, TS4 3BW, UK  
29

30  
31 [Jane@janeshaw.net](mailto:Jane@janeshaw.net)  
32  
33

34  
35 Dawn Carnes PhD, Institute of Population Health Sciences, Barts and The London School of  
36  
37 Medicine and Dentistry, Queen Mary University of London, UK  
38

39  
40 [d.carnes@qmul.ac.uk](mailto:d.carnes@qmul.ac.uk)  
41  
42

43  
44 Andrea Dompieri Furlan, Toronto Rehabilitation Institute, University Health Network,  
45  
46 Department of Medicine, University of Toronto, Institute for Work & Health, Toronto  
47  
48 Canada  
49

50  
51 [Andrea.furlan@uhn.ca](mailto:Andrea.furlan@uhn.ca)  
52  
53

54  
55  
56 Colin Bernard Tysall, UNTRAP Warwick University, SUCE Coventry University, UK  
57

58  
59 [colin@tysall.co.uk](mailto:colin@tysall.co.uk)  
60

1  
2  
3 Henry Adjei, Warwick Clinical Trials Unit, Warwick Medical School, University of  
4  
5 Warwick, Coventry CV4 7AL, UK

6  
7  
8 [H.Adjei@warwick.ac.uk](mailto:H.Adjei@warwick.ac.uk)  
9

10  
11  
12 Chockalingam Muthiah, Warwick Clinical Trials Unit, Warwick Medical School, University  
13  
14 of Warwick, Coventry CV4 7AL, UK

15  
16  
17 [c.muthiah@warwick.ac.uk](mailto:c.muthiah@warwick.ac.uk)  
18

19  
20  
21 Jennifer Noyes, Department of Pain Medicine, Murray Building, The James Cook University  
22  
23 Hospital, Middlesbrough, TS4 3BW, UK

24  
25  
26 [j.noyes@nhs.net](mailto:j.noyes@nhs.net)  
27

28  
29  
30 Nicole K Y Tang, Department of Psychology, University of Warwick, Coventry  
31  
32 CV4 7AL, UK

33  
34  
35 [N.Tang@warwick.ac.uk](mailto:N.Tang@warwick.ac.uk)  
36

37  
38  
39 Stephanie JC Taylor, Institute of Population Health Sciences, Barts and The London School  
40  
41 of Medicine and Dentistry, Queen Mary University of London, UK

42  
43  
44 [s.j.c.taylor@qmul.ac.uk](mailto:s.j.c.taylor@qmul.ac.uk)  
45

46  
47  
48 Martin Underwood, Warwick Clinical Trials Unit, Warwick Medical School, University of  
49  
50 Warwick, Coventry CV4 7AL, UK and University Hospitals Coventry and Warwickshire,  
51  
52 Clifford Bridge Road Coventry CV2 2DX, UK

53  
54  
55 [M.Underwood@warwick.ac.uk](mailto:M.Underwood@warwick.ac.uk)  
56  
57  
58  
59  
60

1  
2  
3 Adrian Willis, Warwick Clinical Trials Unit, Warwick Medical School, University of  
4  
5 Warwick, Coventry CV4 7AL, UK  
6

7  
8 [Adrian.Willis@warwick.ac.uk](mailto:Adrian.Willis@warwick.ac.uk)  
9

10  
11  
12 Sam Eldabe, Department of Pain Medicine, Murray Building, The James Cook University  
13  
14 Hospital, Middlesbrough, TS4 3BW, UK

15  
16  
17 seldabe@nhs.ne  
18

19  
20  
21 Corresponding Author: Harbinder Kaur Sandhu, Warwick Clinical Trials Unit, Warwick  
22  
23 Medical School, University of Warwick, Coventry CV4 7AL, UK

24  
25  
26 [Harbinder.K.Sandhu@warwick.ac.uk](mailto:Harbinder.K.Sandhu@warwick.ac.uk)  
27  
28  
29

### 30 31 **Abstract**

32  
33 Aims and objectives: The I-WOTCH intervention is designed to support people with chronic  
34  
35 non-malignant pain to withdraw from opioids using education, group cohesion, problem  
36  
37 solving, motivation, one to one tailored planning and monitoring and reflection to enhance and  
38  
39 encourage self-management of pain.  
40

41  
42  
43  
44 Methods: The theoretical basis of the I-WOTCH intervention included the design of complex  
45  
46 interventions (The Medical Research Council Framework) behaviour change framework and  
47  
48 psychological theories to support mechanisms of behaviour change, linking components of the  
49  
50 intervention together and overall content and structure of the programme. The I-WOTCH  
51  
52 intervention was based on previous work of self-management of chronic pain (COPERS).  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Results: Based on previous literature on self-management of pain, opioid withdrawal and  
4 feedback from two PPI meetings (n=19) as part of the North East and North Cumbria Clinical  
5 Research Network, we were able to adapt and develop content and structure of the I-WOTCH  
6 Intervention. Feedback included the target behaviour change to be reduction in opioid  
7 consumption and engagement with the I-WOTCH programme. Motivation was also agreed to  
8 be important and the use of case studies to demonstrate successful opioid withdrawal and  
9 education on reduction of side effects and having a “trade-off” encouraging other strategies to  
10 manage pain (in this case self-management). The intervention is delivered by a trained I-  
11 WOTCH clinician and a lay facilitator with experience of opioid reduction. After piloting the  
12 final I-WOTCH structure was agreed including a detailed facilitator manual to deliver the  
13 intervention; participant material including handout, an educational DVD and relaxation and  
14 mindfulness CD; My Opioid Manager (adapted); and a tapering App for clinical facilitators  
15 that generated a tailored tapering plan for each participant.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 Conclusions: We have designed an opioid reduction intervention package suitable for testing  
36 in a randomised controlled trial.  
37  
38  
39  
40  
41

#### 42 **Article Summary: Strengths and limitations**

- 43 1. The I-WOTCH intervention is based on theoretical underpinning.
- 44 2. The I-WOTCH intervention content and structure was designed with input from patient  
45 and public involvement.
- 46 3. A training package to deliver the I-WOTCH Intervention for facilitators was developed and  
47 piloted.
- 48 4. At the time of designing the intervention there was limited previous work and information  
49 to inform content of the intervention.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Key words:** Opioid withdrawal, medication reduction, behaviour change, chronic non cancer  
4 pain, self-management, intervention development  
5  
6

7 **Total word count:** 3,060  
8  
9

## 10 **Introduction**

11  
12  
13  
14  
15 Pain, and pain related disorders, continue to be the leading cause of disability and disease  
16 burden globally (1), with low back pain reported as the leading cause of years lived with  
17 disability. In England at least eight million people (15% of the population) have moderate to  
18 severe persistent (chronic) pain (2) defined as *pain that lasts or recurs for more than three*  
19 *months.*(3) Over the past few decades, there has been a global epidemic of opioid prescribing  
20 for chronic non cancer pain. A 2020 systematic review found that 30 percent of people with  
21 chronic non-malignant pain are prescribed opioid medication and, globally, this has steadily  
22 increased until recently with time. (4) In the UK prescribing rates have decreased slightly over  
23 recent years, however the number of prescriptions still remains high.(5) Long term use of  
24 opioids can lead to tolerance and result in the loss of effective pain relief. Adverse  
25 consequences include opioid induced hyperalgesia, endocrine disorders and hypogandism,  
26 drowsiness, a high risk of dependency, opioid use disorder, sleep apnoea, immune suppression,  
27 and falls leading to increased fractures (particularly a risk in the elderly population), and  
28 death.(6) There is also an increased risk for overdose and potential for sexual dysfunction, with  
29 limited strategies to help with risk mitigation and interventions to help people with chronic  
30 non-malignant pain withdraw from opioids.(7) A 2020 systematic review evaluating the  
31 efficacy of opioid de-prescribing interventions in randomised controlled trials for patients with  
32 chronic non-cancer pain found ten patient focused RCT interventions and two clinician focused  
33 interventions. However, the authors were unable to recommend any particular deprescribing  
34 strategy due to the small number of studies and heterogeneous data.(4)  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Current recommendations on opioid tapering are based on best practice and guidelines which need to be supported by further evidence.(8) The current paper describes the development of a multi-component opioid tapering programme (incorporating group and one to one sessions) as part of the I-WOTCH study (Improving the Wellbeing of Opioid Treated Chronic Pain), funded by the National Institute of Health Research [14/224/04] This paper complements the study protocol paper.(9)

## Methods

The I-WOTCH intervention was developed in collaboration with the target population (those with chronic non-malignant pain and experience of opioid use), and employed theory and evidence based implementation (with the view of implementation in the real world should it be effective) and included digital technologies to generate opioid tapering plans.(10) The Medical Research Council Framework (11) for designing complex interventions and core theoretical principles was used to inform content, structure, and delivery of the intervention.

Key stages of the intervention development are outlined in figure 1. Adjustment and adaptation to the intervention were implemented in line with feedback received from stakeholders (service users, clinicians and facilitators delivering the I-WOTCH intervention).

### **Aims and objectives of the I-WOTCH intervention**

In line with the overall study, the aims of the I-WOTCH intervention were to:

- 1) To reduce opioid and healthcare use for people with chronic non-malignant pain
- 2) To increase self-efficacy (confidence to reduce opioid medication and implement self-management strategies of pain)
- 3) To improve quality of life and help people live better with pain

### Objectives:

- 1) To provide education using a range of teaching methods; group discussion, problem solving, experiential learning and case studies.
- 2) To provide an environment which enhances motivation through group cohesion and one to one support.
- 3) To provide an overall cost-effective intervention to be implemented in healthcare services.

Defining the aims and objectives enabled us to consider what we wanted to achieve, how and for what purpose. In addition, we were aware of potential facilitators and barriers that could influence engagement with the intervention and the procedures of the trial. Figure 2 shows the direction of travel we were aiming for and what we needed to consider when designing the detail of intervention and mechanism of behaviour change.

### **Patient and public involvement**

During the development stages of I-WOTCH, we held two PPI meetings with the Clinical Research Network (North East and Cumbria) at The James Cook University Hospital (South Tees Hospitals NHS Foundation Trust). A total of nineteen volunteer participants (people with chronic pain and experience of opioid therapy and/or opioid tapering) attended. Discussions were facilitated by members of the study team (HS, DC, JS and SE) and included, intervention structure and design, content (topics to cover which would potentially increase motivation and confidence to taper opioids), length of programme, where the intervention should be delivered, support during opioid tapering (including frequency of contact with healthcare professionals) and delivery of the intervention (who should deliver the intervention) (Table 1). In addition to this, two lay advisors who were apart of the I-WOTCH study recruited via Universities/User Teaching, (13) gave considerable input into the design and training of the intervention.

Table 1: Feedback from PPI Informing Intervention Development

Discussion topic	Feedback informing intervention development
Behaviour change	<p>Agreed aims should be a reduction in opioid consumption and engagement in the I-WOTCH programme.</p> <p>Behaviour change needs to be accepted before opioid reduction can occur.</p>
Understanding motivation to change behaviour	<p>Changing medication and reducing medication can be motivated by:</p> <p>i) a trade-off to fill the deficit of the effect of the drug (something else needed that is as effective as the drug they would lose)</p> <p>ii) reduction in side effects</p> <p>Use of case studies of people who had stopped taking opioids and that were successful would be useful.</p>
Content and topics to be covered	<p>The intervention would benefit from being informative (opioid education, especially long term consequences, pros and cons of opioid use and managing withdrawal).</p> <p>The following topics were recommended to be included:</p> <ul style="list-style-type: none"> <li>• What is Pain</li> <li>• Acceptance – pain and learning to live better with pain</li> <li>• Impact of pain – and integrate this information with taking medication (Opioids), why and how?</li> <li>• The importance of hobbies and having a distraction to manage the pain</li> <li>• Offer alternative non-pharmacological ways of coping, e.g. mindfulness and relaxation</li> <li>• Incorporate movement</li> <li>• Guidance on posture and exercise/activity</li> <li>• Pacing – not over doing things</li> </ul>
Dependency vs addiction	<p>It was felt important to distinguish between dependency and addiction, as some were concerned about the stigma and label attached to opioid users for long term pain.</p>
Delivery of I-WOTCH Intervention, who?	<p>Feedback favoured the course to be delivered by a HCP and lay facilitator someone who had experience of long term pain and opioid use/tapering.</p>
Structure of Intervention	<p>Group and individual care approaches were valued.</p> <p>Length of the proposed programme (3-day group sessions and ongoing one to one support) was supported.</p> <p>The duration of intervention was not viewed as burdensome given that some had people who have experienced severe withdrawal symptoms, and therefore ongoing support over the 8 to 10 weeks is needed.</p>

	There was a consensus that a group-based format would be optimal because of the potential for social comparison, social validation and development of social support within a group setting. Volunteers identified the impact of opioid use on enhanced day-to-day activities as important evaluation outcomes, including: work productivity, looking after children, and overall functioning.
Communication during study	Volunteers welcomed the idea of having a study website to give participants an opportunity to be updated about the study as a whole and progress.

### **Opioid Tapering and Behaviour Change**

The target behaviour change was defined as the participants engaging in the I-WOTCH intervention, reducing participant opioid use, and implementing non-pharmacological strategies of pain management. The bio-psychosocial framework (14) and Michie's taxonomy of behaviour change was consulted, in particular the COM-B model (Capability, Opportunity, Motivation).(15) Capability includes psychological capability (can patients engage in the necessary thought processes needed to engage in the tapering processes?) and physical capability (do participants have the capacity to engage in the tapering?). Psychological capability is broken down to cognitive functioning and executive functioning. To promote cognitive functioning (which includes a range of mental abilities such as learning, problem solving and attention) we produced handouts of material covered on each day the programme. This allowed opportunity for participants to recap over the core messages and information in their own time. We also included time for group reflection at the start of each session and summarising discussions at the end of each of the group days (with opportunities for questions). In addition to this we developed an educational DVD, a mindfulness CD and relaxation CD for each participant. By providing material to take home we were giving participants an opportunity to revisit and take in the information at their own pace.(16) Executive functioning includes the capacity to plan and think, explore challenges that may occur (for example fear of withdrawal symptoms), stay focused on the goal (opioid reduction) and resist temptation.(17)

1  
2  
3 In the I-WOTCH intervention we gave participants opportunity to set goals (through an  
4 educational session and support in generating goals related to opioid tapering and their general  
5 life). We also encouraged self-reflection to identify perceived barriers and facilitators to  
6 tapering and gave further guidance to overcome the perceived barriers in the tailored one to  
7 one support sessions with the clinical facilitator. Physical capability refers to whether the  
8 participants exposed to the I-WOTCH Intervention felt they had the right skills to engage in  
9 the tapering of their opioids, this may include management of withdrawal, confidence and  
10 having structure and support in place. The I-WOTCH intervention was designed to help  
11 participants adapt and put into place lifestyle changes.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 Opportunity is the second component of the COM-B model. For this we explored factors  
26 external to the individual that would promote opioid tapering. For example, physical  
27 opportunity which includes, costs of opioids and travel, access and availability, developing a  
28 tapering plan (being clear and informative of who and how this would be developed) and  
29 enhancing communication between the clinical facilitator and participant through motivational  
30 interviewing during the tapering processes. Social opportunity, we referred to what other  
31 factors may impact the decision to taper such as stigma and cultural beliefs.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Motivation, this refers to both the cognitive motivation and emotional processes to energise  
43 and direct the behaviour change of opioid tapering. Reflective processes included exploring  
44 perceptions and meaning of chronic pain during the group sessions as well as beliefs about  
45 tapering, possible outcomes concerns and self-efficacy. There was opportunity to evaluate and  
46 be reflective during the group sessions as well as one to one support. Automatic processes refer  
47 to the emotional responses which may occur during the I-WOTCH intervention and these  
48 include anxiety, fear, stress, and low mood. All topics were covered in the group sessions  
49 including recognition of thoughts and emotions and management strategies.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Each component of the I-WOTCH intervention was informed and mapped on to behaviour  
4 change taxonomy's (BCTv1). The intervention also drew on psychological theories of self-  
5 efficacy,(18) Theory of planned behaviour and reasoned action,(19, 20) social learning (21)  
6 and group based interventions,(22) cognitive behaviour-change, (23) motivational interviewing  
7 (24) and evidence based interventions for self-managing chronic pain (COPERS) (25)  
8 described in Table 2.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 2: Behaviour change taxonomy and opioid tapering

I-WOTCH Group based sessions day 1 (week 1)	Aims	Theoretical Underpinnings	Behaviour Change Taxonomy
Introductions, group work, aims	To allow participants to introduce themselves to the group, encourage participation in a safe and relaxed environment, explore expectations and discuss the I-WOTCH course aims	Social cognitive theory, Bio-psychosocial theory	Improve bonding and group cohesion. Breaking barriers and encouraging self and social awareness
What Causes Pain? (Pain information)	To increase understanding about long-term pain	Biopsychosocial theory Principles of self-efficacy and acceptance	Credible Source
Living With Pain (Opioid education I)	To increase understanding about use of opioids for long term pain and encourage participants to start questioning their own knowledge and beliefs about opioids and why they take them	Biopsychosocial theory Theory of planned behaviour and reasoned action Health Beliefs	Information about health consequences
Acceptance	To understand and start to accept pain, with a view to implementing self-management strategies as reduction of opioids occurs	Acceptance and Self-management of chronic pain	Goal setting Commitment
Attention Control & Distraction	To learn how to focus the mind away from pain thoughts and use of opioids	Cognitive behaviour change Self-management of chronic pain Health beliefs	Distraction
Distraction activity – drawing	An opportunity to practice distraction activity and socially interact with group informally	Cognitive behaviour change Social learning	Behavioural practice Distraction
Good days, bad days - Pain, bearable or not?	To reinforce that pain is not just	Biopsychosocial theory	Information and antecedents

	physiological, it is psychological, social and an emotional phenomenon	Health beliefs	Information about health consequences Re-attribution of behaviour
The pain cycle (including opioids) and breaking the pain cycle	To explain and identify unhelpful factors in the pain cycle and learn strategies to break the cycle	Biopsychosocial Theory Health beliefs	Behaviour Substitution (adding in other behaviours to break cycle)
Posture and movement	To promote body awareness, posture and muscle weakness (Managing pain without opioids)	Theory of planned behaviour and reasoned action	Guidelines on exercise, physical therapy principles, Mindfulness
Relaxation and breathing	To reduce muscle tension and introduce breathing as a relaxation technique	Cognitive behaviour change Self-management of chronic pain	Behavioural practice Distraction Body changes
Summary of the day	To consolidate learning of the day and outline aims for group day 2.	Acceptance and principles of self-efficacy	Action planning Verbal persuasion about capability
<b>I-WOTCH group based Sessions Day 2 (week 2)</b>	<b>Aims</b>	<b>Theoretical Underpinnings</b>	<b>Behaviour Change Taxonomy</b>
Reflections from day 1	To understand and empathise with the group	Social learning Self-efficacy	Improve bonding and group cohesion, social cognitive theory
Stress-busting for Health: Action planning, problem solving, pacing, SMART goal setting	To help the participants logically and systematically identify problems, free think solutions, set achievable goals and create action plans, as a means of escaping the pain cycle	Cognitive behaviour change Theory of planned behaviour and reasoned action	Goal setting Comparative imagining of future outcomes Reduce negative emotions Problem solving
Withdrawal symptoms, Case studies (Opioid education II)	To discuss potential withdrawal symptoms that participants might experience if their taper is too quick	Health beliefs Social learning	Social comparison (drawing attention to others' performance to allow comparison with the person's own performance) Credible source Comparative imagining of future outcomes



1 2 3 4 5 6 7	Distraction activity – origami	To learn how to focus the mind away from pain thoughts and use of opioids	Cognitive behaviour change Social learning	Behavioural practice Distraction
8 9 10 11 12 13 14 15 16 17 18	Identifying and overcoming barriers to change	Introduce ideas about unhelpful thoughts, automatic thoughts and errors in thinking. To identify reasons why people stay in the pain cycle, and barriers to change. Introduce positive reframing	Cognitive behaviour change Self-management of pain	Problem solving Reduce negative emotions Framing/reframing
19 20 21 22 23	Mindful attention control	To introduce Mindfulness as a tool to train attention and distract from pain	Principles of mind body therapies and biofeedback and visualisation	Behavioural practice Distraction Body changes
24 25 26	Balance and stretch	To promote body awareness and core strength	Guidelines on exercise, physical therapy principles	Demonstration of behaviour Behavioural practice
27 28 29 30 31 32 33 34 35	Summary of the day	To consolidate learning of the day and outline aims for final group day 3. A reminder to attend the one to one appointment with the clinical facilitator.	Acceptance and principles of self-efficacy	Action planning Verbal persuasion about capability
36 37 38	I-WOTCH group based Sessions Day 3 (week 3)	Aims	Theoretical Underpinnings	Behaviour Change Taxonomy
39 40 41 42 43	Reflections from day two	To understand and empathise with the group and ascertain current thoughts	Social learning Self-efficacy	Review of behaviour
44 45 46 47 48	Anger, irritability and frustration	Identifying reasons for negative emotions and implementing goal setting and action planning	Cognitive behaviour change Theory of planned behaviour and reasoned action	Reduce negative emotions Goal setting Action planning
49 50 51 52 53 54 55	Relationships: Getting the most from your healthcare team (Part1)	To reflect on consulting behaviour and promote effective communication and constructive consultations	Biopsychosocial theory Theory of planned behaviour and reasoned action	Information about antecedents Instruction on how to perform a behaviour (communication skills)
56 57 58 59 60	Relationships (Part 2) Listening skills	To improve listening and communication skills	Biopsychosocial theory Theory of planned behaviour and	Social support (emotional)

		reasoned action	
Managing setbacks and non-drug management techniques	To know what to do when experiencing a setback or a flare up	Cognitive behaviour change Self-efficacy	Anticipated regret Focus on past success
Mindful distraction activity –colouring	To learn how to focus the mind away from pain thoughts and use of opioids	Principles of mind body therapies and biofeedback and visualisation	Behavioural practice Distraction Body changes
Stretch	To learn how to stretch muscles gently with low risk of injury and pain	Biopsychosocial theory Self-efficacy Principles of acceptance	Demonstration of behaviour Behavioural practice
Mindfulness of Thoughts & Senses	To learn how to apply mindfulness of thoughts by detaching emotion from reality, to appreciate ‘the now’	Principles of mind body therapies and biofeedback and visualisation	Distraction
Summary of the day	To consolidate the days learning.	Acceptance and principles of self-efficacy	Action planning
Summary of the course	To clarify learning from past 3 group days and motivation to continue with opioid reduction	Acceptance and principles of self-efficacy	Review of behaviour Verbal persuasion about capability
<b>One to one session</b>	<b>Aim</b>	<b>Theoretical Underpinnings</b>	<b>Behaviour Change Taxonomy</b>
Interaction one: face to face with clinical facilitator	To reflect on group learning days, agree tapering goals and generate tapering plan	Cognitive behaviour change Motivational Interviewing	Goal setting behaviour Action planning Graded task Pros and cons
Interaction two: 30 minute via telephone call with clinical facilitator	To reflect on progress and offer support during the tapering process	Cognitive behaviour change Motivational interviewing	Review behaviour Behavioural contract (adapted – as generated plan written) Social reward (congratulating on effort made and progress towards tapering-verbal)
Interaction three: 30 minute via telephone with	To reflect on progress and offer support during the	Cognitive behaviour change Motivational	Identification of self as role model (their own behaviour may

clinical facilitator	tapering process	interviewing	be an example to others as they taper)
Interaction four: face to face with clinical facilitator	To reflect on progress so far and goals and discuss goals for future	Cognitive behaviour change Motivational interviewing	Review behaviour Review outcome goal If applicable: discrepancy between current behaviour and goal Feedback on behaviour Goal setting (behaviour) Goal setting (outcome) Action planning

### **Feasibility Testing**

Funding from the Hambleton and Richmond Clinical Commissioning Group for a community pain management service allowed us to test the feasibility of the I-WOTCH Intervention. Seven people were trained by the study team to deliver the intervention (3 community team clinicians 2 nurses and 2 volunteer patients). Two courses were observed to evaluate how the course content was delivered and received by both the group facilitators and the group participants (five participants in total). Discussions included, what worked well, what did not work well, and whether participants felt that the aims and objectives of the programme were met and suggestions for changes.

The second stage of feasibility was as part of the pilot phase of the randomised controlled trial and involved facilitator training for the trial. Two groups were delivered in Coventry. From both stages of feasibility testing feedback was taken on board and adaptations implemented for the training (Table 3) and course content and structure (Table 4)

Table 3: Feedback and changes pilot phases I and II- Training

Feedback (Pilot phase I and II) – Training and facilitator feedback	Changes implemented
Facilitators agreed it is useful to go through the manual step by step, to gain familiarity with each component and navigate through the different stages. They preferred this rather than go through generic topics.	We incorporated this information into the training and prior to a group being delivered if needed the study team helped to arrange meetings between the facilitators.
Facilitators felt it would be useful to all material emailed prior to the training to allow time to read and become familiar with the manual.	Throughout the I-WOTCH study all course material was sent to facilitators prior to training.
Facilitators suggested that during the training it would be useful to actually practice some of the sessions.	Where possible during the training days we incorporated case studies, role play as well as experiential learning of mindfulness and using the tapering app to calculate opioid reduction doses.
Facilitators suggested that it would be useful if the course slides were numbered in correspondence to the sections in the manual.	All course slides numbered and added to manual as reference.
Facilitators also suggested that it would be useful to include rational of each topic into the manual, as it helps with their understanding of each topic and explanation to participants.	Rational for each topic was included in the manual.

Table 4: Feedback and changes pilot phases I and II- Course content and structure

Feedback (Pilot phase I and II) participant feedback	Changes implemented
During pilot phase I, feedback favoured to spread the group sessions over three weeks (one group day a week). This was to help with consolidation of information and learning between sessions and also felt less burdensome.	The I-WOTCH group structure then through the study was delivered within the format of one group session a week (every Monday for three weeks).
It was suggested the balance session works well after posture, to allow more understanding and connection with body.	This was changed in the I-WOTCH programme, balance and stretch was introduced on day 2 of the programme and posture and movement on day 1 of the programme.
Day 1 presented with a lot of opioid educational information and it was suggested to help with understanding of this topic to split them over two days.	The opioid educational information was split over two days (day 1 and day 2 of the programme).
It was also suggested to move pacing after the pain cycle has been discussed, to help with the understanding of why pacing is important and can help break the unhelpful cycle.	The pain cycle was introduced and on day 1 of the programme and pacing was moved to day two of the programme.

During Pilot phase I, patients welcomed an educational DVD to help with the learning.	As part of I-WOTCH we produced an I-WOTCH education DVD which is used in the delivery of the programme, participants are able to then take this home and watch with their family and friends or keep as a resource for themselves.
---	--


Overall, the feedback regarding the content of programme was positive. Participants felt that the distraction techniques worked well and helped break up the sessions. They also valued understanding the link between mood and pain and found the case studies useful in helping to motivate them to start their own journey of reducing their opioids. Facilitators and participants in both pilot phases reported that it was an informative interactive course. Observations showed good delivery and interaction between facilitators and participants, good use of questions and answer session and role play. Both facilitators and patients agreed it may have been more interactive with a larger group

### **Final I-WOTCH Intervention**

The final I-WOTCH Intervention was agreed based on feedback and piloting. (Fig 2) it consists of group day 1 (delivered week one), group day two (delivered week two), a one to one consultation with the an I-WOTCH trained nurse (also in week 2 and after group day two), group day three (week three) and then two telephone consultations and final and a final face to face consultation to offer continual support for tapering. Each component of the intervention builds on previous knowledge and experience, and where the one to one consultation allows consolidation and tailoring of advice and support for tapering. At the beginning of the intervention the learning is centred on pain and opioid education, with day two of the programme then introducing changes in beliefs and adapting different strategies as reduction of opioids occur. It is at this point tailoring support and motivational interviewing to action a change in beliefs is promoted through the one to one support sessions with an opportunity for

further regulation and group cohesion/support on the wider impact of opioid reduction and long term behaviour change. The further one to one support promotions, self-regulation, reflection and monitoring.

Figure 2: Final model of I-WOTCH Intervention



### **One to one consultations**

The one-to-one sessions with a trained I-WOTCH nurse were based on a motivational interviewing model.(26) The aims of MI are to enhance behaviour change through a patient-centred framework, where the patient is able explore personal goals, ambivalence to change and reach self-actualisation in a supportive environment. We trained the I-WOTCH nurses on the five principles of motivational interviewing: Expressing empathy through reflective learning, Expressing empathy through reflective listening, developing discrepancy between participant goals or values (related to opioid tapering and pain management) and their current behaviour, avoiding argument and direct confrontation, adjusting to client resistance to reducing opioid reduction rather than opposing it directly and supporting self-efficacy and optimism. The one-to-one consultations included a review of medication, reflection on the

1  
2  
3 opioid education and group session where case studies and information were presented and  
4  
5 exploring any challenges to opioid tapering such as concerns about withdrawal. Nurses were  
6  
7 also trained to calculate total opioid daily dose and how to use that to produce a tapering regime  
8  
9 according to the I-WOTCH study protocol. Although MI has been widely applied in substance  
10  
11 misuse there are limited data available for its use in opioid cessation for people with chronic  
12  
13 non cancer pain. A 2020 pilot study testing motivational interviewing opioid tapering in post  
14  
15 joint arthroplasty surgery found a 62% increase in the rate of return to baseline opioid use after  
16  
17 surgery (HR 1.62; 95%CI 1.06–2.46;  $p = 0.03$ ).<sup>(27)</sup> Opioid tapering conversations maybe  
18  
19 challenging and each participant will bring their own experiences and motivation to change,  
20  
21 however by using MI as a tool we encouraged I-WOTCH facilitators to support participants in  
22  
23 their tapering journey.<sup>(28)</sup>

### **One to one tapering – App**

24  
25 We adopted an opioid tapering regimen based on the Mayo Clinic experience as it provided  
26  
27 some evidence to support the notion that slow tapering is unlikely to be associated with severe  
28  
29 withdrawal symptoms and therefore likely to facilitate adherence.<sup>(29)</sup> This consisted of a 10%  
30  
31 reduction of the original total daily dose every 7 days until a 30% of the original daily dose is  
32  
33 reached. This is followed by a weekly decrease by 10% of the remaining dose. The 10% may  
34  
35 be rounded up to suit prescribing. For the calculation of equianalgesic doses we used the tables  
36  
37 from the Faculty of Pain Medicine.<sup>(30)</sup> In order to ensure standardisation of tapering  
38  
39 methodology across sites and various opioid preparations the team developed a tapering App  
40  
41 for use by the I-WOTCH trained nurses across sites. The I-WOTCH tapering App was  
42  
43 developed by JN and SE working with the CTU programming team (HA, CM and AW) and  
44  
45 provided to the nurses on a handheld tablet. The I-WOTCH tapering App was based on a  
46  
47 mathematical algorithm applying the Mayo clinic regime while accounting for UK commercial  
48  
49 preparations. Nurses used the App to generate a participant specific tapering plan, which was  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 automatically synchronised to the CTU team where it was printed and posted to the participant  
4 for information and GP for prescribing.  
5  
6

7  
8 The I-WOTCH trained nurse entered the total daily dose of the participant-specific opioid  
9 preparation into the home screen of the App (e.g. 60mg oxycodone/day). The App algorithm  
10 then calculated 10% of the total daily dose and rounded this up or down to suit prescribing. All  
11 tablet, capsule or patch denominations of all opioid preparations were tabulated and added to  
12 the App to ensure the algorithm not only produced a 10% per week tapering regime but also a  
13 recommended various prescribing methods (e.g., oxycodone 35 mg could be prescribed as 30  
14 and 5mg or 20,10 and 5mg tablets or 10,10,10 and 5mg tablets).  
15  
16

17 For patch preparations we advised participants to taper using their original opioid if 10% was  
18 not achievable (e.g., 12mcg of fentanyl being the smallest step down), the app algorithm was  
19 adjusted to recommend a 20% taper over a two-week period. Lowest dosage patch  
20 preparations were finally converted to slow release morphine equianalgesic doses and tapered  
21 accordingly.  
22  
23

### 24 **My Opioid manager**

25  
26 The My Opioid Manager™ Book and App is the output of a project of Toronto Rehabilitation  
27 Institute, University Health Network. In 2010, Dr. Andrea Furlan, a Physician and Scientist at  
28 Toronto Rehabilitation Institute, developed a tool for physicians prescribing opioids for  
29 patients with chronic non-cancer pain. In 2012, the Opioid Manager™ was converted to an  
30 App for smartphones and tablets. The My Opioid Manager Book (and App) is intended to  
31 complement the Opioid Manager™ by providing the same information in a format that can be  
32 used by people with chronic pain who are on opioids, or by people who are not on opioids but  
33 who might be considering this option to help manage their chronic pain. The goal of My Opioid  
34 Manager is preparing the patient for upcoming consultations with their healthcare provider.  
35  
36 Some of the topics discussed include: understanding the causes of various types of pains, uses  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 of opioids and the side effects and risks, managing pain by tracking opioid trials, and tips on  
4 using opioids. For this study we Anglicised the content in terms of language used as well as  
5 name of medication brands and pictures to be more representative of the UK population.  
6  
7  
8  
9

### 10 **Venue for delivering the intervention**

11  
12 Where possible the I-WOTCH intervention is delivered in the community. Factors to consider  
13 when booking a venue include, access to building, parking and public transport links, a room  
14 to accommodate participants and facilitators with chairs and equipment, stairs, lifts, kitchen  
15 facilities and room for equipment such as flipchart, laptop screen, speakers and internet access.  
16  
17  
18  
19  
20

### 21 **I-WOTCH facilitator Training**

22  
23 The delivery–receipt–enactment chain of the I-WOTCH intervention provided a framework for  
24 training of facilitators and defining dosage received for participants to promote behaviour  
25 change (opioid tapering).(31) The I-WOTCH training included two full days for all facilitators  
26 (clinical and lay facilitators) and an additional day for clinical facilitators only, to learn the  
27 clinical aspects of tapering, opioid specific education, generating tapering plans and  
28 motivational interviewing for the one to one consultations. The design of the training package  
29 and implementation was adapted to Kolb’s experiential learning cycle (training, experience and  
30 reflective observation).(32) The training days gave all facilitators exposure to the different  
31 components of the intervention through education and use of case studies. Trainers were given  
32 copies of the I-WOTCH manual and all participant intervention materials. Throughout the  
33 training days facilitators had the opportunity to ask questions and get clarity on any of the  
34 topics being covered. At the end of the training a short assessment was completed by each  
35 facilitator. If any of the facilitators scored below 70% they were then contacted by phone to go  
36 over any areas needing further explanation and offered further training if needed.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Discussion**

We have used a methodical approach to developing an intervention to help people taking opioids for chronic pain to reduce opioid intake. This has been based on underpinning theory, the best available empirical evidence, and consultation with lay people. It has been piloted in and adapted in light of feedback. The I-WOTCH intervention has the potential to both help people reduce their opioid use and improve their overall quality of life. The I-WOTCH intervention is now being tested in the I-WOTCH trial. The trial protocol is published elsewhere.

## **Conclusion**

We have designed an opioid reduction intervention package suitable for testing in a randomised controlled trial.

## **Collaborators I-WOTCH team:**

Sharisse Alleyne, University of Warwick, Charles Abraham, Deakin University, Shyam Balasubramanian, Department of Anaesthesia & Pain Medicine University Hospitals Coventry and Warwickshire NHS Trust, Lauren Betteley, University of Warwick, Katie Booth, University of Warwick, Kirstie Haywood, University of Warwick, Sheeja Manchira Krishnan, The University of York, Ranjit Lall, University of Warwick. Andrea Manca, The University of York. Dipesh Mistry, University of Warwick, Vivien P Nichols, University of Warwick, Emma Padfield, University of Warwick, Anisur Rahman, Kate Seers, University of Warwick, University College London, Cynthia Paola Iglesias Urrutia,.

## **Contributors**

All authors read and approved the manuscript. HS and SE are Co-Chief Investigators and oversee the running of the study. All named authors contributed to the design and/or delivery of the I-WOTCH intervention. HS, SE, JS and DC were involved in the design of the I-WOTCH intervention and design and delivery of facilitator training. CBT contributed to the

1  
2  
3 design and delivery of the I-WOTCH intervention, providing feedback on all materials and a  
4 trained facilitator. ADF developed My Opioid Manager, the content was anglicised for this  
5 study and also contributed to the design of the overall I-WOTCH intervention. SE, JN HA, CM  
6 and AW developed the I-WOTCH Opioid tapering App. MU, NYKT and SJCT contributed to  
7 the design of the intervention, training manuals and to this manuscript.  
8  
9

### 14 **Funding**

15  
16 This project has received funding from the National Institute for Health Research (NIHR),  
17 Health Technology Assessment (HTA) (project number 14/224/04). The views and opinions  
18 expressed therein are those of the authors and do not necessarily reflect those of the HTA,  
19 NIHR, NHS or the Department of Health.  
20  
21  
22  
23  
24

### 25 **Ethical Approval**

26  
27 Ethics approval was given by Yorkshire & The Humber - South Yorkshire Research Ethics  
28 Committee on September 13<sup>th</sup>, 2016 **16/YH/0325**.  
29  
30  
31  
32

### 33 **Competing interests**

34  
35 SE is the Chair of the specialised pain CRG at NHS England, he is Chief investigator and  
36 principal investigator of a number of NIHR and Industry funded trials, he has received personal  
37 fees from Medtronic Ltd, Mainstay Medical, Boston Scientific Corp for consultancy work. His  
38 department has received research funding from the National Institute of Health Research,  
39 Medtronic Ltd and Boston Scientific Corp. HS is director of Health Psychology Services Ltd,  
40 providing psychological services for a range of health related conditions. NT received grant  
41 funding as PI and CoI from NIHR for other projects  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 MU is chief investigator or co-investigator on multiple previous and current research grants  
52 from the UK National Institute for Health Research, Arthritis Research UK and is a co-  
53 investigator on grants funded by the Australian NHMRC. He was an NIHR Senior Investigator  
54 until March 2021. He has received travel expenses for speaking at conferences from the  
55  
56  
57  
58  
59  
60

1  
2  
3 professional organisations hosting the conferences. He is a director and shareholder of Clinvivo  
4  
5 Ltd that provides electronic data collection for health services research. He is part of an  
6  
7 academic partnership with Serco Ltd, funded by the European Social Fund, related to return to  
8  
9 work initiatives. He receives some salary support from University Hospitals Coventry and  
10  
11 Warwickshire He is a co-investigator on three NIHR funded studies receiving additional  
12  
13 support from Stryker Ltd. He has accepted honoraria for teaching/lecturing from consortium  
14  
15 for advanced research training in Africa. Until March 2020 he was an editor of the NIHR  
16  
17 journal series, and a member of the NIHR Journal Editors Group, for which he received a fee.  
18  
19 AF is author of the My Opioid Manager book and App distributed in iTunes and Google Play.  
20  
21 Both book and app are free of charge. She is author of the Opioid Manager App, a paid app  
22  
23 distributed only in iTunes for healthcare professionals. The app is owned by UHN, the hospital  
24  
25 where AF works. AF does not get any financial benefit from the sales of the app. AF has a  
26  
27 monetized YouTube channel since January 2021 that contains some videos about opioids and  
28  
29 opioid tapering. Since April 2021, AF has a unrestricted educational grant to maintain an online  
30  
31 self-assessment opioid course for healthcare professionals in Canada. The funding is provided  
32  
33 by the Canadian Generics Pharmaceutical Association (CGPA). The funding organization has  
34  
35 no role in the preparation, approval, recruitment of participants, or data analysis of the course  
36  
37 content. Responsibility for the course content is solely that of the authors.  
38  
39  
40  
41  
42  
43

#### 44 **Acknowledgments**

45  
46 We would like to thank Ms Sally Brown for her valuable input in the development of the  
47  
48 intervention. We would also like to thank all of our PPI volunteers and the Clinical Research  
49  
50 Network (North East and Cumbria) for hosting the events which provided valuable insight to  
51  
52 the structure and content of the intervention. We would like to thank our clinical and lay  
53  
54 facilitators who attended training, delivered the intervention and provided valuable feedback.  
55  
56 We would like to thank all participants involved in the pilot stages of the intervention. We  
57  
58  
59  
60

would also like to thank Dr Alison Hipwell for her contribution to the intervention development and Dr Celia Bernstein and Dr Jodie Westhead for their contribution to the I-WOTCH study.

## **References**

1. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*. 2017 Sep 16;390(10100):1211-59.
2. Bridges S. Health Survey for England 2011, Volume 1, Health , social care and lifestyles. HSCIC; 2012. p. 291-306.
3. International Association for the Study of Pain. Chronic Pain has arrived in the ICD-11 [Internet]. Washington: International Association for the study of Pain: 2019 Jan 17 [cited 2021 April 30]. Available from <https://www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?ItemNumber=8340>.
4. Mathieson S, Maher CG, Ferreira GE, Hamilton M, Jansen J, McLachlan AJ, Underwood M, Lin CW. Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of Randomised Trials. *Drugs*. 2020 Jul 31:1-4.
5. Openprescribing, [Cited May 2021] Available from <https://openprescribing.net/analyse/#org=stp&numIds=4.7.2&denom=nothing&selectedTab=chart>

- 1  
2  
3 6. Baldini A, Von Korff M, Lin EH. A review of potential adverse effects of long-term opioid  
4 therapy: a practitioner's guide. The primary care companion to CNS disorders. 2012;14(3).  
5  
6  
7  
8  
9 7. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C,  
10 Deyo RA Ann Intern Med. 2015 Feb 17;162(4):276-86. doi: 10.7326/M14-2559. Review.  
11  
12 PMID:25581257  
13  
14  
15  
16  
17 8. Sandhu H, Underwood M, Furlan AD, Noyes J, Eldabe S. What interventions are effective  
18 to taper opioids in patients with chronic pain?. *bmj*. 2018 Sep 27;362.  
19  
20  
21  
22  
23 9. Sandhu H, Underwood M, Furlan AD, Noyes J, Eldabe S. What interventions are effective  
24 to taper opioids in patients with chronic pain?. *bmj*. 2018 Sep 27;362.  
25  
26  
27  
28  
29 10. O'Cathain A, Croot L, Sworn K, Duncan E, Rousseau N, Turner K, Yardley L, Hodinott  
30 P. Taxonomy of approaches to developing interventions to improve health: a systematic  
31 methods overview. Pilot and feasibility studies. 2019 Dec;5(1):1-27.).  
32  
33  
34  
35  
36  
37 11. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and  
38 evaluating complex interventions: the new Medical Research Council guidance. *BMJ*  
39 (Clinical research ed). 2008;337:a1655.]  
40  
41  
42  
43  
44  
45 12. Carnes D, Homer K, Underwood M, Pincus T, Rahman A, Taylor S.J.C. Pain  
46 management for chronic musculoskeletal conditions: the development of an evidence based  
47 and theory informed pain self-management course. *BMJ Open*. 2013; 3:e003534.doi:10.1136  
48  
49  
50  
51  
52  
53 13. Univeristy of Warwick. UNTRAP Leaflet [Internet]. Coventry: Univeristy of Warwick  
54 [Cited May 2021]. Available from  
55 [https://warwick.ac.uk/fac/cross\\_fac/healthatwarwick/untrap/untrapeaflet.pdf](https://warwick.ac.uk/fac/cross_fac/healthatwarwick/untrap/untrapeaflet.pdf).  
56  
57  
58  
59  
60


- 1  
2  
3 14. Turk DC, Wilson H, Swanson KS, Ebert M, Kerns R. The biopsychosocial model of pain  
4 and pain management. Cambridge: Cambridge University Press; 2011.  
5  
6  
7
- 8  
9 15. Abraham C, Michie S. A taxonomy of behavior change techniques  
10 used in interventions. *Health Psychol* 2008;27:379–87  
11  
12  
13
- 14  
15 16. Richards, Georgia C.a,\*; Lluka, Lesley J.b; Smith, Maree T.c; Haslam, Catherined;  
16 Moore, Brendanc,e; O'Callaghan, Jamese; Strong, Jennyf Effects of long-term opioid  
17 analgesics on cognitive performance and plasma cytokine concentrations in patients with  
18 chronic low back pain: a cross-sectional pilot study, *PAIN Reports*: July/August 2018  
19  
20  
21  
22  
23  
24  
25
- 26  
27 17. Diamond A. Executive functions. *Annual review of psychology*. 2013 Jan 3;64:135-68.  
28  
29  
30
- 31  
32 18. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. *Psychological*  
33 *review*. 1977 Mar;84(2):191.  
34  
35  
36  
37
- 38  
39 19. Ajzen I, Fishbein M. Understanding attitudes and predicting social  
40 behavior. London: Pearson Education, 1980  
41  
42  
43  
44
- 45  
46 20. Ajzen I, Fishbein M. Belief, attitude, intention and behaviour: an introduction to theory  
47 and research. Higher Education; 1976.  
48  
49  
50  
51
- 52  
53 21. Bandura A. Social foundations of thought and action. Englewood Cliffs, NJ.  
54 1986;1986(23-28).  
55  
56  
57  
58  
59  
60

- 1  
2  
3 22. Morley S, Shapiro DA, Biggs J. Developing a treatment manual for attention  
4 management in chronic pain. *Cogn Behav Ther* 2004;33:1–11.  
5  
6  
7 23. Kuhl J, Beckmann J, editors. *Action control: From cognition to behavior*. Springer  
8 Science & Business Media; 2012 Dec 6.  
9  
10  
11  
12  
13  
14 24. Hayes SC, Strosahl KD, Wilson KG. *Acceptance and commitment therapy: an*  
15 *experiential approach to behavior change*. New York: Guilford Press, 2004.  
16  
17  
18  
19  
20  
21 25. Carnes D, Homer K, Underwood M, Pincus T, Rahman A, Taylor SJ. Pain management  
22 for chronic musculoskeletal conditions: the development of an evidence-based and theory-  
23 informed pain self-management course. *BMJ open*. 2013 Nov 1;3(11).  
24  
25  
26  
27  
28  
29  
30 26. Miller WR, Rollnick S. *Motivational interviewing: Preparing to change addictive*  
31 *behaviour*. New York: Guilford. 1991.  
32  
33  
34  
35  
36  
37 27. Hah JM, Trafton JA, Narasimhan B, Krishnamurthy P, Hilmoe H, Sharifzadeh Y,  
38 Huddleston JI, Amanatullah D, Maloney WJ, Goodman S, Carroll I. Efficacy of  
39 motivational-interviewing and guided opioid tapering support for patients undergoing  
40 orthopedic surgery (MI-Opioid Taper): A prospective, assessor-blind, randomized controlled  
41 pilot trial. *EClinicalMedicine*. 2020 Nov 1;28:100596.).  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51 28. Crawley A, Murphy L, Regier L, McKee N. Tapering opioids using motivational  
52 interviewing. *Canadian Family Physician*. 2018 Aug 1;64(8):584-7.  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 29. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic  
4  
5 noncancer pain: evidence and recommendations for everyday practice. In Mayo Clinic  
6  
7 Proceedings 2015 Jun 1 (Vol. 90, No. 6, pp. 828-842). Elsevier.  
8  
9  
10 30. Faculty of Pain Medicine of Royal College of Anaesthetists. Dose equivalents and  
11  
12 changing opioids [Internet]. London: Faculty of Pain Medicine of Royal College of  
13  
14 Anaesthetists. Available from: [https://fpm.ac.uk/opioids-aware-structured-approach-opioid-](https://fpm.ac.uk/opioids-aware-structured-approach-opioid-prescribing/dose-equivalents-and-changing-opioids)  
15  
16 [prescribing/dose-equivalents-and-changing-opioids](https://fpm.ac.uk/opioids-aware-structured-approach-opioid-prescribing/dose-equivalents-and-changing-opioids)  
17  
18  
19  
20  
21 31. Sandhu HK, Abraham C, Alleyne S, Balasubramanian S, Betteley L, Booth K, Carnes D,  
22  
23 Furlan AD, Haywood K, Urrutia CP, Lall R. Testing a support programme for opioid  
24  
25 reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled  
26  
27 trial protocol. BMJ open. 2019 Aug 1;9(8):e028937.  
28  
29  
30  
31  
32  
33 32. Kolb DA. Experience as the source of learning and development. Upper Sadle River:  
34  
35 Prentice Hall. 1984.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1: Stages of I-WOTCH intervention development

**Legend:**

COPERS - coping with persistent pain, effectiveness research into self-management (12)


I-WOTCH- Improving the Wellbeing of Opioid Treated Chronic Pain

NIHR – National Institute of Health Research

PPI - Patient and Public Involvement

RCT – Randomised Controlled Trial

Figure 2: Reducing Opioids for patients with chronic non cancer pain



# BMJ Open

## The development and testing of an opioid tapering self-management intervention for chronic pain – I-WOTCH

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053725.R1
Article Type:	Original research
Date Submitted by the Author:	08-Dec-2021
Complete List of Authors:	Sandhu, Harbinder; University of Warwick Warwick Medical School, Clinical Trials Unit Shaw, Jane; James Cook University Hospital Carnes, Dawn; Queen Mary University of London Barts and The London School of Medicine and Dentistry, Institute of Population Health Sciences Furlan, Andrea; Toronto Rehabilitation Institute; University of Toronto Faculty of Medicine Tysall, Colin; University of Warwick, UNTRAP; Coventry University, SUCE Adjei, Henry; University of Warwick Warwick Medical School, Warwick Clinical Trials Unit Muthiah, Chockalingam; University of Warwick, Warwick Clinical Trials Unit Noyes, Jennifer; James Cook University Hospital, Department of Pain Medicine Tang, Nicole; University of Warwick, Psychology Taylor, Stephanie; Queen Mary University of London Barts and The London School of Medicine and Dentistry, Wolfson Institute of Population Health Underwood, Martin; University of Warwick Warwick Medical School, Warwick Clinical Trials Unit Willis, Adrian; University of Warwick, Warwick Clinical Trials Unit Eldabe, Sam; James Cook University Hospital, Department of Pain Medicine
<b>Primary Subject Heading</b>:	Medical management
Secondary Subject Heading:	Patient-centred medicine, Pharmacology and therapeutics, Rehabilitation medicine
Keywords:	Pain management < ANAESTHETICS, Rehabilitation medicine < INTERNAL MEDICINE, MEDICAL EDUCATION & TRAINING, PAIN MANAGEMENT, PRIMARY CARE, Clinical trials < THERAPEUTICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 The development and testing of an opioid tapering self-management  
4  
5  
6 intervention for chronic pain: I-WOTCH  
7

8 Harbinder Kaur Sandhu, Jane Shaw, Dawn Carnes, Andrea Dompieri Furlan, Colin Bernard  
9  
10 Tysall, Henry Adjei, Chockalingam Muthiah, Jennifer Noyes, Nicole K Y Tang , Stephanie JC  
11  
12 Taylor, Martin Underwood, Adrian Willis, Sam Eldabe, On behalf of the I-WOTCH Team  
13  
14  
15

16  
17  
18 Harbinder Kaur Sandhu, Warwick Clinical Trials Unit, Warwick Medical School, University  
19  
20 of Warwick, Coventry CV4 7AL, UK  
21

22  
23 [Harbinder.K.Sandhu@warwick.ac.uk](mailto:Harbinder.K.Sandhu@warwick.ac.uk)  
24  
25

26  
27  
28 Jane Shaw, The James Cook University Hospital, Middlesbrough, TS4 3BW, UK  
29

30  
31 [Jane@janeshaw.net](mailto:Jane@janeshaw.net)  
32  
33

34  
35 Dawn Carnes PhD, Institute of Population Health Sciences, Barts and The London School of  
36  
37 Medicine and Dentistry, Queen Mary University of London, UK  
38

39  
40 [d.carnes@qmul.ac.uk](mailto:d.carnes@qmul.ac.uk)  
41  
42

43  
44 Andrea Dompieri Furlan, Toronto Rehabilitation Institute, University Health Network,  
45  
46 Department of Medicine, University of Toronto, Institute for Work & Health, Toronto  
47  
48 Canada  
49

50  
51 [Andrea.furlan@uhn.ca](mailto:Andrea.furlan@uhn.ca)  
52  
53

54  
55 Colin Bernard Tysall, UNTRAP Warwick University, SUCE Coventry University, UK  
56

57  
58 [colin@tysall.co.uk](mailto:colin@tysall.co.uk)  
59  
60

1  
2  
3 Henry Adjei, Warwick Clinical Trials Unit, Warwick Medical School, University of  
4  
5  
6 Warwick, Coventry CV4 7AL, UK

7  
8 [H.Adjei@warwick.ac.uk](mailto:H.Adjei@warwick.ac.uk)  
9

10  
11  
12 Chockalingam Muthiah, Warwick Clinical Trials Unit, Warwick Medical School, University  
13  
14 of Warwick, Coventry CV4 7AL, UK

15  
16  
17 [c.muthiah@warwick.ac.uk](mailto:c.muthiah@warwick.ac.uk)  
18

19  
20  
21 Jennifer Noyes, Department of Pain Medicine, Murray Building, The James Cook University  
22  
23 Hospital, Middlesbrough, TS4 3BW, UK

24  
25  
26 [j.noyes@nhs.net](mailto:j.noyes@nhs.net)  
27

28  
29  
30 Nicole K Y Tang, Department of Psychology, University of Warwick, Coventry  
31  
32 CV4 7AL, UK

33  
34  
35 [N.Tang@warwick.ac.uk](mailto:N.Tang@warwick.ac.uk)  
36

37  
38  
39 Stephanie JC Taylor, Wolfson Institute of Population Health, Barts and The London School  
40  
41 of Medicine and Dentistry, Queen Mary University of London, UK

42  
43  
44 [s.j.c.taylor@qmul.ac.uk](mailto:s.j.c.taylor@qmul.ac.uk)  
45

46  
47  
48  
49 Martin Underwood, Warwick Clinical Trials Unit, Warwick Medical School, University of  
50  
51 Warwick, Coventry CV4 7AL, UK and University Hospitals Coventry and Warwickshire,  
52  
53 Clifford Bridge Road Coventry CV2 2DX, UK

54  
55  
56 [M.Underwood@warwick.ac.uk](mailto:M.Underwood@warwick.ac.uk)  
57  
58  
59  
60



1  
2  
3 Adrian Willis, Warwick Clinical Trials Unit, Warwick Medical School, University of  
4  
5 Warwick, Coventry CV4 7AL, UK  
6

7 [Adrian.Willis@warwick.ac.uk](mailto:Adrian.Willis@warwick.ac.uk)  
8  
9

10  
11  
12 Sam Eldabe, Department of Pain Medicine, Murray Building, The James Cook University  
13  
14 Hospital, Middlesbrough, TS4 3BW, UK  
15

16  
17 [seldabe@nhs.net](mailto:seldabe@nhs.net)  
18  
19

20  
21 Corresponding Author: Harbinder Kaur Sandhu, Warwick Clinical Trials Unit, Warwick  
22  
23 Medical School, University of Warwick, Coventry CV4 7AL, UK  
24

25  
26 [Harbinder.K.Sandhu@warwick.ac.uk](mailto:Harbinder.K.Sandhu@warwick.ac.uk)  
27

28  
29 **Word count: 3396**  
30

### 31 32 **Abstract**

33  
34 Objectives: To describe the design, development and pilot of a multi-component intervention  
35  
36 aimed at supporting withdrawal of opioids for people with chronic non-malignant pain for  
37  
38 future evaluation in the Improving the Wellbeing of Opioid Treated CHronic pain (I-WOTCH)  
39  
40 randomised controlled trial.  
41  
42  
43  
44  
45

46  
47 Design: The I-WOTCH intervention draws on previous literature and co-creation with  
48  
49 stakeholders (patient and public involvement). Intervention mapping and development  
50  
51 activities of Behaviour Change Taxonomy are described.  
52  
53  
54

55  
56 Setting: The intervention development was conducted by a multidisciplinary team with clinical,  
57  
58 academic and service user perspectives. The team had expertise in the development and testing  
59  
60

1  
2  
3 of complex health behaviour interventions, opioid tapering and pain management in primary  
4 and secondary care, I.T programming, and software development - to develop an opioid  
5 tapering App.  
6  
7  
8  
9

10  
11  
12 Participants: The I-WOTCH trial participants are adults (18 years and over) with chronic non-  
13 malignant pain using strong opioids for at least three months and on most days in the preceding  
14 month.  
15  
16  
17  
18  
19

20  
21 Outcomes: A multi-component self-management support package to help people using opioids  
22 for chronic non-malignant pain reduce opioid use.  
23  
24  
25  
26  
27

28 Interventions and Results: Receiving information on the impact of long-term opioid use, and  
29 potential adverse effects were highlighted as important facilitators in making the decision to  
30 reduce opioids. Case studies of those who have successfully stopped taking opioids were also  
31 favoured as a facilitator to reduce opioid use. Barriers included the need for a “trade-off to fill  
32 the deficit of the effect of the drug”. The final I-WOTCH intervention consists of an 8 to 10  
33 week programme incorporating: education; problem solving; motivation; group and one to one  
34 tailored planning; reflection and monitoring. A detailed facilitator manual was developed to  
35 promote consistent delivery of the intervention across the UK.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 **Conclusions:** We describe the development of an opioid reduction intervention package  
47 suitable for testing in the I-WOTCH randomised controlled trial.  
48  
49  
50  
51

52  
53 **Trial Registration:** ISRCTN49470934  
54

55  
56 **Article summary**  
57

58 **Strengths and limitations:**  
59  
60

- 1
- 2
- 3 1. The I-WOTCH Intervention draws on psychological and behaviour change frameworks.
- 4
- 5
- 6 2. The I-WOTCH intervention was co-created with key stakeholders including patient and
- 7 public involvement (those with chronic-non-malignant pain and experience of opioid use
- 8 and/or tapering).
- 9
- 10
- 11
- 12
- 13
- 14 3. The pilot phases and feasibility testing gave valuable feedback and changes were made to
- 15 the intervention accordingly.
- 16
- 17
- 18
- 19
- 20
- 21 4. At the time of designing the intervention there was limited previous work and information
- 22 to inform content of the intervention.
- 23
- 24
- 25
- 26
- 27

### **Funding Statement:**

28 This project has received funding from the National Institute for Health Research (NIHR),  
29 Health Technology Assessment (HTA) (project number 14/224/04). SJCT supported by the  
30 National Institute for Health Research ARC North Thames. The views and opinions expressed  
31 therein are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS  
32 or the Department of Health.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### **Competing Interests**

44 SE is the Chair of the specialised pain CRG at NHS England, he is Chief investigator and  
45 principal investigator of a number of NIHR and Industry funded trials, he has received personal  
46 fees from Medtronic Ltd, Mainstay Medical, Boston Scientific Corp for consultancy work. His  
47 department has received research funding from the National Institute of Health Research,  
48 Medtronic Ltd and Boston Scientific Corp. HS is director of Health Psychology Services Ltd,  
49 providing psychological services for a range of health related conditions. NKYT is chief  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 investigator or co-investigator of other chronic pain related projects funded by the NIHR,  
4 MRC, Warwick-Wellcome Translational Partnership.  
5

6  
7 MU is chief investigator or co-investigator on multiple previous and current research grants  
8 from the UK National Institute for Health Research, Arthritis Research UK and is a co-  
9 investigator on grants funded by the Australian NHMRC. He was an NIHR Senior Investigator  
10 until March 2021. He has received travel expenses for speaking at conferences from the  
11 professional organisations hosting the conferences. He is a director and shareholder of Clinvivo  
12 Ltd that provides electronic data collection for health services research. He is part of an  
13 academic partnership with Serco Ltd, funded by the European Social Fund, related to return to  
14 work initiatives. He receives some salary support from University Hospitals Coventry and  
15 Warwickshire He is a co-investigator on three NIHR funded studies receiving additional  
16 support from Stryker Ltd. He has accepted honoraria for teaching/lecturing from consortium  
17 for advanced research training in Africa. Until March 2020 he was an editor of the NIHR  
18 journal series, and a member of the NIHR Journal Editors Group, for which he received a fee.  
19

20 AF is author of the My Opioid Manager book and App distributed in iTunes and Google Play.  
21 Both book and app are free of charge. She is author of the Opioid Manager App, a paid app  
22 distributed only in iTunes for healthcare professionals. The app is owned by UHN, the hospital  
23 where AF works. AF does not get any financial benefit from the sales of the app. AF has a  
24 monetized YouTube channel since January 2021 that contains some videos about opioids and  
25 opioid tapering. Since April 2021, AF has an unrestricted educational grant to maintain an  
26 online self-assessment opioid course for healthcare professionals in Canada. The funding is  
27 provided by the Canadian Generics Pharmaceutical Association (CGPA). The funding  
28 organization has no role in the preparation, approval, recruitment of participants, or data  
29 analysis of the course content. Responsibility for the course content is solely that of the authors.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 SJCT is chief investigator or co-investigator on multiple previous and current research grants  
4  
5 from the UK National Institute for Health Research.  
6  
7  
8  
9

## 10 **Article Summary: Strengths and limitations**

11  
12 **Key words:** Opioid withdrawal, medication reduction, behaviour change, chronic non  
13  
14 malignant pain, self-management, intervention development  
15  
16  
17  
18

## 19 **Introduction**

20  
21 Pain, and pain related disorders, continue to be the leading cause of disability and disease  
22  
23 burden globally (1), with low back pain making the largest contribution to years lived with  
24  
25 disability. In England at least eight million people (15% of the population) have moderate to  
26  
27 severe persistent (chronic) pain (2) defined as *pain that lasts or recurs for more than three*  
28  
29 *months.*(3) Over the past few decades, there has been a global epidemic of opioid prescribing  
30  
31 for chronic non-malignant pain. A 2020 systematic review found that 30 percent of people with  
32  
33 chronic non-malignant pain are prescribed opioid medication and, globally, this has steadily  
34  
35 increased until recently with time. (4) In the UK prescribing rates have decreased slightly over  
36  
37 recent years, however the number of prescriptions remains high.(5) Long term use of opioids  
38  
39 leads tolerance and loss of effective pain relief. Adverse consequences include opioid induced  
40  
41 hyperalgesia, endocrine disorders and hypogonadism, drowsiness, a high risk of dependency,  
42  
43 opioid use disorder, sleep apnoea, sexual dysfunction, immune suppression, falls leading to  
44  
45 increased fractures (particularly a risk in the elderly population) and increased risk for overdose  
46  
47 and death.(6) There are limited strategies to help with risk mitigation and interventions to help  
48  
49 people with chronic non-malignant pain withdraw from opioids.(7) A 2020 systematic review  
50  
51 found ten randomised controlled trials (n=835) of patient-focused opioid de-prescribing  
52  
53 interventions targeting people with chronic non-malignant pain. These included: dose  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 reduction protocols (weekly reduction of 10 percent); opioid replacement including  
4 (buprenorphine, morphine sulphate or oxycodone hydrochloride or varenicline; non-  
5 pharmacological therapies including mindfulness (vs active control or support group);  
6 therapeutic interactive voice response programme (vs usual care); meditation; cognitive  
7 behavioural therapy (vs usual care); and electroacupuncture (vs sham). The primary outcome  
8 was mean reduction of daily dose in morphine milligram equivalents). Only one study reported  
9 a statistically significant difference in the daily dose between groups in favour of the  
10 intervention (a study using a dose tapering protocol) (Mean Difference -27.9 MME/day, 95%CI  
11 -41.1 to -14.7).(8) None of these interventions reported increases in opioid cessation in the  
12 intervention groups. Overall, the authors were unable to recommend any particular  
13 deprescribing strategy due to the small number of studies and heterogeneity of the data.(4)  
14  
15 Current recommendations on opioid tapering are based on best practice and guidelines which  
16 need to be supported by further evidence.(9) Here we describe the development of a multi-  
17 component opioid tapering programme (incorporating group and one to one sessions) as part  
18 of the I-WOTCH study (Improving the Wellbeing of Opioid Treated Chronic Pain), funded by  
19 the National Institute of Health Research [14/224/04]. The I-WOTCH study protocol has been  
20 published previously.(10)  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

## 45 **Methods**

46  
47 The I-WOTCH intervention was developed in collaboration with the target population (those  
48 with chronic non-malignant pain and experience of opioid use). It employed theory and  
49 evidence based implementation (with a view to implementation in the real world should it be  
50 effective) and included digital technologies to generate opioid tapering plans.(11) The Medical  
51 Research Council Framework (12) for designing complex interventions, evidence based  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 interventions (13) and core theoretical principles was used to inform the design of content,  
4 structure, and delivery of the intervention.  
5  
6

7  
8 Key stages of the intervention development, figure 1. Adjustment and adaptation to the  
9 intervention were implemented in-line with feedback received from stakeholders (service  
10 users, clinicians and facilitators delivering the I-WOTCH intervention).  
11  
12  
13  
14  
15  
16

### 17 **Aims and objectives of the I-WOTCH intervention**

18  
19 In line with the overall study, the aims of the I-WOTCH intervention were:  
20  
21

- 22 1) To reduce opioid and healthcare use for people with chronic, non-malignant pain
- 23 2) To increase study participants' self-efficacy (confidence) to reduce opioid medication  
24 and implement self-management strategies of pain.  
25
- 26 3) To improve quality of life and help people live better with pain.  
27  
28  
29

30  
31 Objectives:

- 32 1) To provide education using a range of teaching methods; group discussion, problem  
33 solving, experiential learning and case studies.  
34
- 35 2) To provide an environment which enhances motivation to reduce opioid use through  
36 group cohesion and one to one support.  
37
- 38 3) To provide an overall cost-effective intervention to be implemented in healthcare  
39 services.  
40  
41  
42  
43  
44  
45

46 Defining the aims and objectives enabled us to consider what we wanted to achieve, how and  
47 for what purpose. In addition, we were aware of potential facilitators and barriers that could  
48 influence engagement with the intervention and the procedures of the trial. Figure 2 shows the  
49 direction of travel we were aiming for and what we needed to consider when designing the  
50 detail of intervention and mechanism of behaviour change.  
51  
52  
53  
54  
55  
56  
57  
58  
59

### 60 **Patient and public involvement**

During the development stages of I-WOTCH, we held two PPI meetings with the Clinical Research Network (North East and Cumbria) at The James Cook University Hospital (South Tees Hospitals NHS Foundation Trust). A total of nineteen volunteer participants (people with chronic pain and experience of opioid therapy and/or opioid tapering) attended. Discussions were facilitated by members of the study team (HS, DC, JS and SE) and included, intervention structure and design, content (topics to cover which would potentially increase motivation and confidence to taper opioids), length of programme, where the intervention should be delivered, support during opioid tapering (including frequency of contact with healthcare professionals) and delivery of the intervention (who should deliver the intervention) (Table 1). In addition to this, two lay advisors who were part of the I-WOTCH study recruited via Universities/User Teaching, (14) gave considerable input into the design of, and training to deliver, the intervention.

Table 1: Feedback from PPI Informing Intervention Development

Discussion topic	Feedback informing intervention development
Behaviour change	<p>Agreed aims should be a reduction in opioid consumption and engagement in the I-WOTCH programme.</p> <p>Behaviour change needs to be accepted before opioid reduction can occur.</p>
Understanding motivation to change behaviour	<p>Changing medication and reducing medication can be motivated by:</p> <p>i) a trade-off to fill the deficit of the effect of the drug (something else needed that is as effective as the drug they would lose)</p> <p>ii) reduction in side effects</p> <p>Use of case studies of people who had successfully stopped taking opioids would be useful.</p>
Content and topics to be covered	<p>The intervention would benefit from being informative (opioid education, especially long-term consequences, pros and cons of opioid use and managing withdrawal).</p> <p>The following topics were recommended for inclusion:</p> <ul style="list-style-type: none"> <li>• What is Pain</li> </ul>



	<ul style="list-style-type: none"> <li>• Acceptance – pain and learning to live better with pain</li> <li>• Impact of pain – and integrate this information with taking medication (Opioids), why and how?</li> <li>• The importance of hobbies and having a distraction to manage the pain</li> <li>• Offer alternative non-pharmacological ways of coping, e.g. mindfulness and relaxation</li> <li>• Incorporate movement</li> <li>• Guidance on posture and exercise/activity</li> <li>• Pacing – not over doing things</li> </ul>
Dependency vs addiction	It was felt important to distinguish between dependency and addiction, as some were concerned about the stigma and labels attached to long term opioid use for chronic pain.
Delivery of I-WOTCH Intervention, who?	Feedback favoured the course to be delivered jointly by a HCP* and a lay facilitator (someone who had experience of long term pain and opioid use/tapering).
Structure of Intervention	<p>Group and individual care approaches were valued. Length of the proposed programme (3-day group sessions and ongoing one to one support) was supported. The duration of intervention was not viewed as burdensome given that some had people who have experienced severe withdrawal symptoms, and therefore ongoing support over the 8 to 10 weeks is needed.</p> <p>There was a consensus that a group-based format and group cohesion would be optimal because of the potential for social comparison, social validation and development of social support. Volunteers identified the impact of opioid use on enhanced day-to-day activities as important evaluation outcomes, including: work productivity, looking after children, and overall functioning.</p>
Communication during study	Volunteers welcomed the idea of having a study website to give participants an opportunity to be updated about the study as a whole and progress.

\*HCP Health care professional

### **Opioid Tapering and Behaviour Change**

The target behaviour change was defined as the participants engaging in the I-WOTCH intervention, reducing participant opioid use, and implementing non-pharmacological strategies of pain management. The bio-psychosocial framework (15), Michie's taxonomy of behaviour change and the COM-B framework for behaviour change (Capability, Opportunity,

1  
2  
3 Motivation) were consulted.(16) Capability includes psychological capability (e.g., can  
4 patients engage in the necessary thought processes needed to engage in the tapering processes?)  
5 and physical capability (e.g., do participants have the capacity to engage in the tapering?).  
6  
7 Psychological capability is broken down to cognitive functioning and executive functioning.  
8  
9 To promote cognitive functioning (which includes a range of mental abilities such as learning,  
10 problem solving and attention) we produced handouts of material covered on each day the  
11 programme. This allowed opportunity for participants to recap over the core messages and  
12 information in their own time. We also included time for group reflection at the start of each  
13 session and summarising discussions at the end of each of the group days (with opportunities  
14 for questions). In addition to this we developed an educational DVD, a mindfulness CD and  
15 relaxation CD for each participant (at the time we developed the intervention DVDs and CDs  
16 were still in common use). By providing material to take home we were giving participants an  
17 opportunity to revisit and take in the information at their own pace.(17) Executive functioning  
18 includes the capacity to plan and think, explore challenges that may occur (e.g., fear of  
19 withdrawal symptoms), stay focused on the goal (opioid reduction) and resist temptation.(18)  
20  
21 In the I-WOTCH intervention we gave participants opportunity to set goals (through an  
22 educational session and support in generating goals related to opioid tapering and their general  
23 life). We also encouraged self-reflection to identify perceived barriers and facilitators to  
24 tapering and gave further guidance to overcome the perceived barriers in the tailored one to  
25 one support sessions with the clinical facilitator. Physical capability refers to whether the  
26 participants exposed to the I-WOTCH intervention felt they had the right skills to engage in  
27 the tapering of their opioids, this may include management of withdrawal, confidence and  
28 having structure and support in place. The I-WOTCH intervention was designed to help  
29 participants adapt and put into place lifestyle changes.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Opportunity is the second component of the COM-B model. For this we explored factors  
4 external to the individual that would promote opioid tapering. For example, physical  
5 opportunity which includes, costs of opioids and travel, access and availability, developing a  
6 tapering plan (clear and informative) and enhancing communication between the clinical  
7 facilitator and participant through motivational interviewing during the tapering processes. In  
8 relation to social opportunity, we referred to what other factors may impact the decision to  
9 taper such as stigma and cultural beliefs.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 Motivation, this refers to both the cognitive motivation and emotional processes to energise  
21 and direct the behaviour change of opioid tapering. Reflective processes included exploring  
22 perceptions and meaning of chronic pain during the group sessions as well as beliefs about  
23 tapering, possible outcomes concerns and self-efficacy. There was opportunity to evaluate and  
24 be reflective during the group sessions as well as one to one support. Automatic processes refer  
25 to the emotional responses which may occur during the I-WOTCH intervention and these  
26 include anxiety, fear, stress, and low mood. All topics were covered in the group sessions  
27 including recognition of thoughts and emotions and management strategies.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Each component of the I-WOTCH intervention was informed and mapped on to behaviour  
41 change taxonomy's (BCTv1). The intervention also drew on psychological theories of self-  
42 efficacy (19), Theory of planned behaviour and reasoned action,(20, 21) social learning (22)  
43 and group based interventions,(23) cognitive behaviour-change, (24) motivational interviewing  
44 (25) and evidence based interventions for self-managing chronic pain (COPERS) (26)  
45 described in Table 2.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

I-WOTCH Group based sessions day 1 (week 1)	Aims	Theoretical Underpinnings	Behaviour Change Taxonomy
Introductions, group work, aims	To allow participants to introduce themselves to the group, encourage participation in a safe and relaxed environment, explore expectations and discuss the I-WOTCH course aims	Social cognitive theory Bio-psychosocial theory	Improve bonding and group cohesion. Breaking barriers and encouraging self and social awareness
What Causes Pain? (Pain information)	To increase understanding about long-term pain	Biopsychosocial theory Principles of self-efficacy and acceptance	Credible Source
Living With Pain (Opioid education I)	To increase understanding about use of opioids for long term pain and encourage participants to start questioning their own knowledge and beliefs about opioids and why they take them	Biopsychosocial theory Theory of planned behaviour and reasoned action Health Beliefs	Information about health consequences
Acceptance	To understand and start to accept pain, with a view to implementing self-management strategies as reduction of opioids occurs	Acceptance and Self-management of chronic pain	Goal setting Commitment
Attention Control & Distraction	To learn how to focus the mind away from pain thoughts and use of opioids	Cognitive behaviour change Self-management of chronic pain Health beliefs	Distraction
Distraction activity – drawing	An opportunity to practise distraction	Cognitive behaviour change	Behavioural practice Distraction

Table 2: Behaviour change taxonomy and opioid tapering

	activity and socially interact with group informally	Social learning	
Good days, bad days - Pain, bearable or not?	To reinforce that pain is not just physiological, it is psychological, social and an emotional phenomenon	Biopsychosocial theory Health beliefs	Information and antecedents Information about health consequences Re-attribution of behaviour
The pain cycle (including opioids) and breaking the pain cycle	To explain and identify unhelpful factors in the pain cycle and learn strategies to break the cycle	Biopsychosocial theory Health beliefs	Behaviour Substitution (adding in other behaviours to break cycle)
Posture and movement	To promote body awareness, posture and muscle weakness (Managing pain without opioids)	Theory of planned behaviour and reasoned action	Guidelines on exercise, physical therapy principles Mindfulness
Relaxation and breathing	To reduce muscle tension and introduce breathing as a relaxation technique	Cognitive behaviour change Self-management of chronic pain	Behavioural practice Distraction Body changes
Summary of the day	To consolidate learning of the day and outline aims for group day 2.	Acceptance and principles of self-efficacy	Action planning Verbal persuasion about capability
<b>I-WOTCH group based Sessions Day 2 (week 2)</b>	<b>Aims</b>	<b>Theoretical Underpinnings</b>	<b>Behaviour Change Taxonomy</b>
Reflections from day 1	To understand and empathise with the group	Social learning Self-efficacy	Improve bonding and group cohesion, social cognitive theory
Stress-busting for Health: Action planning, problem solving, pacing, SMART goal setting	To help the participants logically and systematically identify problems, free think solutions, set achievable goals and create action plans, as a means of escaping the pain cycle	Cognitive behaviour change Theory of planned behaviour and reasoned action	Goal setting Comparative imagining of future outcomes Reduce negative emotions Problem solving
Withdrawal symptoms, Case	To discuss potential withdrawal symptoms	Health beliefs	Social comparison (drawing attention to

1 2 3 4 5 6 7 8 9 10 11 12	studies (Opioid education II)	that participants might experience if their taper is too quick	Social learning	others' performance to allow comparison with the person's own performance) Credible source  Comparative imagining of future outcomes
13 14 15 16	Distraction activity – origami	To learn how to focus the mind away from pain thoughts and use of opioids	Cognitive behaviour change  Social learning	Behavioural practice  Distraction
17 18 19 20 21 22 23 24 25 26 27	Identifying and overcoming barriers to change	Introduce ideas about unhelpful thoughts, automatic thoughts and errors in thinking. To identify reasons why people stay in the pain cycle, and barriers to change. Introduce positive reframing	Cognitive behaviour change  Self-management of pain	Problem solving  Reduce negative emotions  Framing/reframing
28 29 30 31 32	Mindful attention control	To introduce Mindfulness as a tool to train attention and distract from pain	Principles of mind body therapies and biofeedback and visualisation	Behavioural practice  Distraction  Body changes
33 34 35 36	Balance and stretch	To promote body awareness and core strength	Guidelines on exercise  Physical therapy principles	Demonstration of behaviour  Behavioural practice
37 38 39 40 41 42 43 44 45	Summary of the day	To consolidate learning of the day and outline aims for final group day 3. A reminder to attend the one to one appointment with the clinical facilitator.	Acceptance and principles of self-efficacy	Action planning  Verbal persuasion about capability
46 47 48	<b>I-WOTCH group based Sessions Day 3 (week 3)</b>	<b>Aims</b>	<b>Theoretical Underpinnings</b>	<b>Behaviour Change Taxonomy</b>
49 50 51 52	Reflections from day two	To understand and empathise with the group and ascertain current thoughts	Social learning  Self-efficacy	Review of behaviour
53 54 55 56 57 58 59 60	Anger, irritability and frustration	Identifying reasons for negative emotions and implementing goal setting and action planning	Cognitive behaviour change  Theory of planned behaviour and reasoned action	Reduce negative emotions  Goal setting  Action planning

Relationships: Getting the most from your healthcare team (Part1)	To reflect on consulting behaviour and promote effective communication and constructive consultations	Biopsychosocial theory  Theory of planned behaviour and reasoned action	Information about antecedents Instruction on how to perform a behaviour (communication skills)
Relationships (Part 2) Listening skills	To improve listening and communication skills	Biopsychosocial theory  Theory of planned behaviour and reasoned action	Social support (emotional)
Managing setbacks and non-drug management techniques	To know what to do when experiencing a setback or a flare up	Cognitive behaviour change  Self-efficacy	Anticipated regret  Focus on past success
Mindful distraction activity –colouring	To learn how to focus the mind away from pain thoughts and use of opioids	Principles of mind body therapies and biofeedback and visualisation	Behavioural practice  Distraction  Body changes
Stretch	To learn how to stretch muscles gently with low risk of injury and pain	Biopsychosocial theory  Self-efficacy Principles of acceptance	Demonstration of behaviour  Behavioural practice
Mindfulness of Thoughts & Senses	To learn how to apply mindfulness of thoughts by detaching emotion from reality, to appreciate ‘the now’	Principles of mind body therapies Biofeedback and visualisation	Distraction
Summary of the day	To consolidate the days learning.	Acceptance and principles of self-efficacy	Action planning
Summary of the course	To clarify learning from past 3 group days and motivation to continue with opioid reduction	Acceptance and principles of self-efficacy	Review of behaviour  Verbal persuasion about capability
<b>One to one session</b>	<b>Aim</b>	<b>Theoretical Underpinnings</b>	<b>Behaviour Change Taxonomy</b>
Interaction one: face to face with clinical facilitator	To reflect on group learning days, agree tapering goals and generate tapering plan	Cognitive behaviour change  Motivational Interviewing	Goal setting behaviour  Action planning  Graded task  Pros and cons
Interaction two: 30 minute via telephone call with clinical	To reflect on progress and offer support during the tapering	Cognitive behaviour change	Review behaviour  Behavioural contract



facilitator	process	Motivational Interviewing	(adapted – as generated plan written) Social reward (congratulating on effort made and progress towards tapering-verbal)
Interaction three: 30 minute via telephone with clinical facilitator	To reflect on progress and offer support during the tapering process	Cognitive behaviour change Motivational Interviewing	Identification of self as role model (their own behaviour may be an example to others as they taper)
Interaction four: face to face with clinical facilitator	To reflect on progress so far and goals and discuss goals for future	Cognitive behaviour change Motivational Interviewing	Review behaviour  Review outcome goal If applicable: discrepancy between current behaviour and goal feedback on behaviour  Goal setting (behaviour)  Goal setting (outcome)  Action planning

### **Feasibility Testing**

Funding from the Hambleton and Richmond Clinical Commissioning Group for a community pain management service allowed us to test the feasibility of the I-WOTCH intervention. Seven people were trained by the study team to deliver the intervention (3 community team clinicians 2 nurses and 2 volunteer patients). Two courses were observed by a member of the study team to evaluate how the course content was delivered and received by both the group facilitators and the group participants (five participants in total). Discussions included, what worked well, what did not work well, and whether participants felt that the aims and objectives of the programme were met and suggestions for changes.



The second stage of feasibility was part of the pilot phase of the randomised controlled trial and involved facilitator training for the trial. Two groups were delivered in Coventry. From both stages of feasibility testing feedback was taken on board and adaptations implemented for the training (Table 3) and course content and structure (Table 4).

Table 3: Feedback and changes pilot phases I and II- Training

Feedback (Pilot phase I and II) – Training and facilitator feedback	Changes implemented
Facilitators agreed it is useful to go through the manual step by step, to gain familiarity with each component and navigate through the different stages. They preferred this rather than going through generic topics.	We incorporated this information into the training and prior to a group being delivered, if needed the study team helped to arrange meetings between the facilitators.
Facilitators felt it would be useful for all material to be emailed prior to the training to allow time for familiarisation with the manual.	Throughout the I-WOTCH study all course material was sent to facilitators prior to training.
Facilitators suggested that during the training it would be useful to actually practice some of the sessions.	Where possible during the training days we incorporated case studies and role play, as well as experiential learning of mindfulness and using the tapering app to calculate opioid reduction doses.
Facilitators suggested that it would be useful if the course slides were numbered in correspondence to the sections in the manual.	All course slides numbered and added to the manual for reference.
Facilitators also suggested that it would be useful to include the rationale for each topic into the manual, as it helped with their understanding of each topic and with their explanation to participants.	Rationale for each topic was included in the manual.

Table 4: Feedback and changes pilot phases I and II- Course content and structure

Feedback (Pilot phase I and II) participant feedback	Changes implemented
During pilot phase I, feedback favoured spreading the group sessions over three weeks (one group day per week). This was to help with consolidation of information and learning between sessions and also felt less burdensome.	In the trial the I-WOTCH group structure was delivered with this format (every Monday where possible for three weeks).
It was suggested the balance session worked well after the session on posture, to allow more understanding and connection with body.	This was changed in the I-WOTCH programme: balance and stretch was introduced on day 2 of

	the programme and posture and movement on day 1 of the programme.
Day 1 presented a lot of educational information on opioids and it was suggested to split this over two days to help support consolidation of understanding	The educational information was split over two days (day 1 and day 2 of the programme).
It was also suggested to move the session on pacing to after the pain cycle has been discussed, to help with the understanding of why pacing is important and can help break the unhelpful cycle.	The pain cycle was introduced and on day 1 of the programme and pacing was moved to day two of the programme.
During Pilot phase I, patients welcomed an educational DVD to help with the learning.	As part of I-WOTCH we produced an I-WOTCH education DVD which is used in the delivery of the programme, participants are able to then take this home and watch with their family and friends or keep as a resource for themselves.

Overall, the feedback regarding the content of programme was positive. Participants felt that the distraction techniques worked well and helped break up the sessions. They also valued understanding the link between mood and pain and found the case studies useful in helping to motivate them to start reducing their opioids. Facilitators and participants in both pilot phases reported that it was an informative interactive course. Observations showed good delivery and interaction between facilitators and participants, good use of questions and answer sessions and role play. Both facilitators and patients agreed it may have been more interactive had the group been larger.

### **Final I-WOTCH Intervention**

The final I-WOTCH intervention. (Fig 3) consists of group day 1 (delivered week one), group day two (delivered week two), a one-to-one consultation with an I-WOTCH trained nurse (also in week 2 and after group day two), group day three (week three) and then two telephone consultations and a final face to face consultation to offer continual support for tapering. Each component of the intervention builds on previous knowledge and experience, and where the one-to-one consultation allows consolidation and tailoring of advice and support for tapering.

1  
2  
3 At the beginning of the intervention the learning is centred on pain and opioid education, with  
4 day two of the programme then introducing changes in beliefs and adapting different strategies  
5 as reduction of opioids occur. It is at this point tailoring support and motivational interviewing  
6 to action a change in beliefs is promoted through the one-to-one support sessions with an  
7 opportunity for further regulation and group cohesion/support on the wider impact of opioid  
8 reduction and long term behaviour change. The further one to ones support, self-regulation,  
9 reflection and monitoring.

### 10 11 12 **One to one consultations**

13  
14  
15 The one-to-one sessions with a trained I-WOTCH nurse were based on a motivational  
16 interviewing (MI) model.(27) The aims of MI are to enhance behaviour change through a  
17 patient-centred framework, where the patient is able explore personal goals, ambivalence to  
18 change and reach self-actualisation in a supportive environment. We trained the I-WOTCH  
19 nurses on the five principles of motivational interviewing: i, expressing empathy through  
20 reflective learning, ii, expressing empathy through reflective listening, iii, developing  
21 discrepancy between participant goals or values (related to opioid tapering and pain  
22 management) and their current behaviour, avoiding argument and direct confrontation, iv,  
23 adjusting to client resistance to reducing opioid reduction rather than opposing it directly and  
24 v, supporting self-efficacy and optimism. The one-to-one consultations included a review of  
25 medication, reflection on the opioid education and group session where case studies and  
26 information were presented and exploring any challenges to opioid tapering such as concerns  
27 about withdrawal. Nurses were also trained to calculate total opioid daily dose and how to use  
28 that to produce a tapering regime according to the I-WOTCH study protocol. Although MI has  
29 been widely applied in substance misuse there are limited data available for its use in opioid  
30 cessation for people with chronic non-malignant pain. A 2020 pilot study testing motivational  
31 interviewing to support opioid tapering in post joint arthroplasty surgery found a 62% increase  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 in the rate of participants returning to baseline opioid use after surgery (HR 1.62; 95%CI 1.06–  
4 2.46; p = 0.03).(28) Opioid tapering conversations maybe challenging and each participant will  
5 bring their own experiences and motivation to change, however by using MI as a tool we  
6 encouraged I-WOTCH facilitators to support participants in their tapering..(29)  
7  
8  
9

### 10 11 12 **One to one tapering – App**

13  
14 We adopted an opioid tapering regimen based on the Mayo Clinic experience as it provided  
15 some evidence to support the notion that slow tapering is unlikely to be associated with severe  
16 withdrawal symptoms and therefore likely to facilitate adherence.(30) This consisted of a 10%  
17 reduction of the original total daily dose every 7 days until a 30% of the original daily dose is  
18 reached. This is followed by a weekly decrease by 10% of the remaining dose. The 10% was  
19 rounded up to suit prescribing. For the calculation of equianalgesic doses we used the tables  
20 from the Faculty of Pain Medicine.(31) In order to ensure standardisation of tapering  
21 methodology across sites and various opioid preparations the team developed a tapering App  
22 for use by the I-WOTCH trained nurses across sites. The I-WOTCH tapering App was  
23 developed by JN and SE working with the Warwick University Clinical Trials Unit  
24 (CTU)programming team (HA, CM and AW) and provided to the nurses on a handheld tablet.  
25  
26 The I-WOTCH tapering App was based on a mathematical algorithm applying the Mayo clinic  
27 tapering regime while accounting for UK commercial preparations. Nurses used the App to  
28 generate a participant specific tapering plan, which was synchronised to the I-WOTCH Trial  
29 database. The study team at Warwick CTU then logged into the centralised trial management  
30 website, printed and posted the tapering plan to the participant for their information and  
31 General Practitioner (GP) for prescribing.  
32  
33

34  
35 The I-WOTCH trained nurse entered the total daily dose of the participant-specific opioid  
36 preparation into the home screen of the App (e.g. 60mg oxycodone/day). The App algorithm  
37 then calculated 10% of the total daily dose and rounded this up or down to suit prescribing. All  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 tablet, capsule or patch denominations of all opioid preparations were tabulated and added to  
4  
5 the App to ensure the algorithm not only produced a 10% per week tapering regime but also  
6  
7 recommended various prescribing methods (e.g., oxycodone 35 mg could be prescribed as 30  
8  
9 and 5mg or 20,10 and 5mg tablets or 10,10,10 and 5mg tablets).

10  
11  
12 For patch preparations we advised participants to taper using their original opioid if 10% was  
13  
14 not achievable (e.g., 12mcg of fentanyl being the smallest step down), the app algorithm was  
15  
16 adjusted to recommend a 20% taper at two-week intervals. Lowest dosage patch preparations  
17  
18 were finally converted to slow release morphine equianalgesic doses and tapered accordingly.  
19  
20  
21  
22

### **My Opioid manager**

23  
24  
25 The My Opioid Manager™ Book and App is the output of a project of Toronto Rehabilitation  
26  
27 Institute, University Health Network. In 2010, Dr. Andrea Furlan, a Physician and Scientist at  
28  
29 Toronto Rehabilitation Institute, developed a tool for physicians prescribing opioids for  
30  
31 patients with chronic non-malignant pain. In 2012, the Opioid Manager™ was converted to an  
32  
33 App for smartphones and tablets. The My Opioid Manager Book (and App) is intended to  
34  
35 complement the Opioid Manager™ by providing the same information in a format that can be  
36  
37 used by people with chronic pain who are on opioids, or by people who are not on opioids but  
38  
39 who might be considering this option to help manage their chronic pain. The goal of My Opioid  
40  
41 Manager is preparing the patient for upcoming consultations with their healthcare provider.  
42  
43 Some of the topics discussed include: understanding the causes of various types of pains, uses  
44  
45 of opioids and the side effects and risks, managing pain by tracking opioid trials, and tips on  
46  
47 using opioids. For this study we Anglicised the content in terms of language used as well as  
48  
49 name of medication brands and pictures to be more representative of the UK population.  
50  
51  
52  
53  
54  
55  
56  
57

### **Venue for delivering the intervention**

1  
2  
3 Where possible the I-WOTCH intervention is delivered in the community. Factors to consider  
4 when booking a venue included, access to building, parking and public transport links, a room  
5 to accommodate participants and facilitators with chairs and equipment, stairs, lifts, kitchen  
6 facilities and room for equipment such as flipchart, laptop screen, speakers and internet access.  
7  
8  
9

### 10 11 12 **I-WOTCH facilitator Training**

13  
14 The delivery–receipt–enactment chain of the I-WOTCH intervention provided a framework for  
15 training of facilitators and defining dosage received for participants to promote behaviour  
16 change (opioid tapering).(32) The I-WOTCH training included two full days for all facilitators  
17 (clinical and lay facilitators) and an additional day for clinical facilitators only, to learn the  
18 clinical aspects of tapering, opioid specific education, generating tapering plans and  
19 motivational interviewing for the one to one consultations. The design of the training package  
20 and implementation was adapted to Kolb’s experiential learning cycle (training, experience and  
21 reflective observation).(33) The training days gave all facilitators exposure to the different  
22 components of the intervention through education and use of case studies. Trainers were given  
23 copies of the I-WOTCH manual and all participant intervention materials. Throughout the  
24 training days facilitators had the opportunity to ask questions and get clarity on any of the  
25 topics being covered. At the end of the training a short assessment was completed by each  
26 facilitator. If any of the facilitators scored below 70% they were then contacted by phone to go  
27 over any areas needing further explanation and offered further training if needed.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 47 **Discussion**

48  
49 We have used a methodological approach to developing an intervention for opioid reduction  
50 for people with chronic non-malignant pain. Based on the COPERS intervention for the  
51 management of pain, best available empirical evidence at the time, and consultation with lay  
52 people we have developed a manualised intervention and training package. It has been piloted,  
53 revised and adapted considering all feedback received. The I-WOTCH intervention has the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 potential to help people reduce their opioid use and improve their overall quality of life. We  
4  
5 are not aware of any other programme of analogous interventions targeting similar populations.  
6  
7 Previous non-pharmacological interventions have included mindfulness, cognitive behaviour  
8  
9 therapy and meditation and the use of electro acupuncture which showed no reduction in the  
10  
11 number of participants who ceased their opioid use.(4) The I-WOTCH intervention differs in  
12  
13 that it combines group and one to one support, with the mechanisms of change and opioid  
14  
15 reduction targeted through peer support, education, case studies, reflection and motivational  
16  
17 interviewing. It is a time and resource intensive intervention, however, having a multi  
18  
19 component intervention will increase the potential to address the complex psychological, social  
20  
21 and physical aspects of opioid tapering. We have developed an opioid tapering App which can  
22  
23 be used to calculate individual opioid tapering plans.  
24  
25  
26  
27

28 The roll out and scalability of the I-WOTCH training has been considered, a step by step  
29  
30 manual with materials to set up and deliver the programme was created. The I-WOTCH  
31  
32 facilitator training can be delivered to groups of clinicians and ongoing support given through-  
33  
34 out the delivery of the intervention. The I-WOTCH trial will allow us to assess: the delivery of  
35  
36 the intervention on a large scale, the training of multiple facilitators and managing the group  
37  
38 element of the programme.  
39  
40  
41

### 42 **Conclusion**

43  
44 We have designed an opioid reduction intervention package suitable for testing in a  
45  
46 randomised controlled trial.  
47  
48  
49

### 50 **Collaborators I-WOTCH team:**

51  
52 Sharisse Alleyne, University of Warwick, Charles Abraham, Deakin University, Shyam  
53  
54 Balasubramanian, Department of Anaesthesia & Pain Medicine University Hospitals Coventry  
55  
56 and Warwickshire NHS Trust, Lauren Betteley, University of Warwick, Katie Booth,  
57  
58  
59  
60



1  
2  
3 University of Warwick, Kirstie Haywood, University of Warwick, Sheeja Manchira Krishnan,  
4 The University of York, Ranjit Lall, University of Warwick. Andrea Manca, The University of  
5 York. Dipesh Mistry, University of Warwick, Vivien P Nichols, University of Warwick, Emma  
6 Padfield, University of Warwick, Anisur Rahman, Kate Seers, University of Warwick,  
7 University College London, Cynthia Paola Iglesias Urrutia,.  
8  
9  
10  
11  
12  
13

### 14 **Contributors**

15  
16 All authors read and approved the manuscript. HS and SE are Co-Chief Investigators and  
17 oversee the running of the study. All named authors contributed to the design and/or delivery  
18 of the I-WOTCH intervention. HS, SE, JS and DC were involved in the design of the I-  
19 WOTCH intervention and design and delivery of facilitator training. CBT contributed to the  
20 design and delivery of the I-WOTCH intervention, providing feedback on all materials and a  
21 trained facilitator. ADF developed My Opioid Manager, the content was anglicised for this  
22 study and also contributed to the design of the overall I-WOTCH intervention. SE, JN HA, CM  
23 and AW developed the I-WOTCH Opioid tapering App. MU, NYKT and SJCT contributed to  
24 the design of the intervention, training manuals and to this manuscript.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

### 37 **Ethical Approval**

38  
39 Ethics approval was given by Yorkshire & The Humber - South Yorkshire Research Ethics  
40 Committee on September 13<sup>th</sup>, 2016 **16/YH/0325**.  
41  
42  
43

### 44 **Acknowledgments**

45  
46 We would like to thank Ms Sally Brown for her valuable input in the development of the  
47 intervention. We would also like to thank all of our PPI volunteers and the Clinical Research  
48 Network (North East and Cumbria) for hosting the events which provided valuable insight to  
49 the structure and content of the intervention. We would like to thank our clinical and lay  
50 facilitators who attended training, delivered the intervention and provided valuable feedback.  
51  
52 We would like to thank all participants involved in the pilot stages of the intervention. We  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 would also like to thank Dr Alison Hipwell for her contribution to the intervention  
4  
5 development and Dr Celia Bernstein and Dr Jodie Westhead for their contribution to the I-  
6  
7 WOTCH study.  
8  
9

10  
11 Figure 1: Stages of I-WOTCH intervention development  
12

13  
14  
15 Figure 2: Reducing opioids for people with chronic non-malignant pain  
16

17  
18 Figure 3: Final model of I-WOTCH intervention  
19

### 20 21 **Data Sharing statement**

22  
23  
24  
25 No additional data available  
26

### 27 28 **References**

- 29  
30  
31  
32 1. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS,  
33  
34 Abdulle AM, Abebo TA, Abera SF, Aboyans V. Global, regional, and national incidence,  
35  
36 prevalence, and years lived with disability for 328 diseases and injuries for 195 countries,  
37  
38 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*.  
39  
40 2017 Sep 16;390(10100):1211-59.  
41  
42  
43  
44 2. Bridges S. Health Survey for England 2011, Volume 1, Health , social care and lifestyles.  
45  
46 HSCIC; 2012. p. 291-306.  
47  
48  
49  
50 3. International Association for the Study of Pain. Chronic Pain has arrived in the ICD-11  
51  
52 [Internet]. Washington: International Association for the study of Pain: 2019 Jan 17 [cited  
53  
54 2021 April 30]. Available from [https://www.iasp](https://www.iasp.org/PublicationsNews/NewsDetail.aspx?ItemNumber=8340)  
55  
56  
57  
58  
59  
60

- 1  
2  
3 4. Mathieson S, Maher CG, Ferreira GE, Hamilton M, Jansen J, McLachlan AJ, Underwood  
4  
5 M, Lin CW. Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of  
6  
7 Randomised Trials. *Drugs*. 2020 Jul 31;1-4.  
8  
9
- 10  
11 5. Openprescribing. [Cited May 2021] Available from  
12  
13 [https://openprescribing.net/analyse/#org=stp&numIds=4.7.2&denom=nothing&selectedTab=](https://openprescribing.net/analyse/#org=stp&numIds=4.7.2&denom=nothing&selectedTab=chart)  
14  
15 [chart](https://openprescribing.net/analyse/#org=stp&numIds=4.7.2&denom=nothing&selectedTab=chart)  
16  
17
- 18  
19 6. Baldini A, Von Korff M, Lin EH. A review of potential adverse effects of long-term opioid  
20  
21 therapy: a practitioner's guide. *The primary care companion to CNS disorders*. 2012;14(3).  
22  
23
- 24  
25 7. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C,  
26  
27 Deyo RA *Ann Intern Med*. 2015 Feb 17;162(4):276-86. doi: 10.7326/M14-2559. Review.  
28  
29 PMID:25581257  
30  
31
- 32  
33 8. Kurita GP, Højsted J, Sjøgren P. Tapering off long-term opioid therapy in chronic non-  
34  
35 cancer pain patients: a randomized clinical trial. *Eur J Pain*. 2018;22(8):1528-1543  
36  
37
- 38  
39 9. Covington EC, Argoff CE, Ballantyne JC, Cowan P, Gazelka HM, Hooten WM, Kertesz  
40  
41 SG, Manhapra A, Murphy JL, Stanos SP Jr, Sullivan MD. Ensuring Patient Protections When  
42  
43 Tapering Opioids: Consensus Panel Recommendations. *Mayo Clin Proc*. 2020  
44  
45 Oct;95(10):2155-2171. doi: 10.1016/j.mayocp.2020.04.025. PMID: 33012347.  
46  
47
- 48  
49 10. Sandhu H, Underwood M, Furlan AD, Noyes J, Eldabe S. What interventions are  
50  
51 effective to taper opioids in patients with chronic pain?. *bmj*. 2018 Sep 27;362.  
52  
53
- 54  
55 11. O'Cathain A, Croot L, Sworn K, Duncan E, Rousseau N, Turner K, Yardley L, Hoddinott  
56  
57 P. Taxonomy of approaches to developing interventions to improve health: a systematic  
58  
59 methods overview. *Pilot and feasibility studies*. 2019 Dec;5(1):1-27.).  
60

- 1  
2  
3 12. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and  
4 evaluating complex interventions: the new Medical Research Council guidance. *BMJ*  
5  
6 (Clinical research ed). 2008;337:a1655.]  
7  
8  
9  
10  
11 13. Carnes D, Homer K, Underwood M, Pincus T, Rahman A, Taylor S.J.C. Pain  
12 management for chronic musculoskeletal conditions: the development of an evidence based  
13 and theory informed pain self-management course. *BMJ Open*. 2013; 3:e003534.doi:10.1136  
14  
15  
16  
17  
18 14. Univeristy of Warwick. UNTRAP Leaflet [Internet]. Coventry: Univeristy of Warwick  
19 [Cited May 2021]. Available from  
20  
21 [https://warwick.ac.uk/fac/cross\\_fac/healthatwarwick/untrap/untrapeaflet.pdf](https://warwick.ac.uk/fac/cross_fac/healthatwarwick/untrap/untrapeaflet.pdf).  
22  
23  
24  
25  
26  
27 15. Turk DC, Wilson H, Swanson KS, Ebert M, Kerns R. The biopsychosocial model of pain  
28 and pain management. Cambridge: Cambridge University Press; 2011.  
29  
30  
31  
32  
33 16. Abraham C, Michie S. A taxonomy of behavior change techniques  
34 used in interventions. *Health Psychol* 2008;27:379–87  
35  
36  
37  
38  
39  
40 17. Richards, Georgia C.a,\*; Lluka, Lesley J.b; Smith, Maree T.c; Haslam, Catherined;  
41 Moore, Brendanc,e; O'Callaghan, Jamese; Strong, Jennyf Effects of long-term opioid  
42 analgesics on cognitive performance and plasma cytokine concentrations in patients with  
43 chronic low back pain: a cross-sectional pilot study, *PAIN Reports*: July/August 2018  
44  
45  
46  
47  
48  
49  
50  
51 18. Diamond A. Executive functions. *Annual review of psychology*. 2013 Jan 3;64:135-68.  
52  
53  
54  
55  
56 19. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. *Psychological*  
57 review. 1977 Mar;84(2):191.  
58  
59  
60


- 1  
2  
3  
4  
5  
6 20. Ajzen I, Fishbein M. Understanding attitudes and predicting social  
7  
8 behavior. London: Pearson Education, 1980  
9  
10  
11  
12 21. Ajzen I, Fishbein M. Belief, attitude, intention and behaviour: an introduction to theory  
13  
14 and research. Higher Education; 1976.  
15  
16  
17  
18 22. Bandura A. Social foundations of thought and action. Englewood Cliffs, NJ.  
19  
20 1986;1986(23-28).  
21  
22  
23  
24  
25  
26 23. Morley S, Shapiro DA, Biggs J. Developing a treatment manual for attention  
27  
28 management in chronic pain. Cogn Behav Ther 2004;33:1–11.  
29  
30 24. Kuhl J, Beckmann J, editors. Action control: From cognition to behavior. Springer  
31  
32 Science & Business Media; 2012 Dec 6.  
33  
34  
35  
36  
37 25. Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment therapy: an  
38  
39 experiential approach to behavior change. New York: Guilford Press, 2004.  
40  
41  
42  
43  
44 26. Carnes D, Homer K, Underwood M, Pincus T, Rahman A, Taylor SJ. Pain management  
45  
46 for chronic musculoskeletal conditions: the development of an evidence-based and theory-  
47  
48 informed pain self-management course. BMJ open. 2013 Nov 1;3(11).  
49  
50  
51  
52  
53 27. Miller WR, Rollnick S. Motivational interviewing: Preparing to change addictive  
54  
55 behaviour. New York: Guilford. 1991.  
56  
57  
58  
59  
60

- 1  
2  
3 28. Hah JM, Trafton JA, Narasimhan B, Krishnamurthy P, Hilmoe H, Sharifzadeh Y,  
4 Huddleston JI, Amanatullah D, Maloney WJ, Goodman S, Carroll I. Efficacy of  
5 motivational-interviewing and guided opioid tapering support for patients undergoing  
6 orthopedic surgery (MI-Opioid Taper): A prospective, assessor-blind, randomized controlled  
7 pilot trial. *EClinicalMedicine*. 2020 Nov 1;28:100596.).  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17 29. Crawley A, Murphy L, Regier L, McKee N. Tapering opioids using motivational  
18 interviewing. *Canadian Family Physician*. 2018 Aug 1;64(8):584-7.  
19  
20  
21  
22  
23  
24 30. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic  
25 noncancer pain: evidence and recommendations for everyday practice. In *Mayo Clinic*  
26 *Proceedings* 2015 Jun 1 (Vol. 90, No. 6, pp. 828-842). Elsevier.  
27  
28  
29  
30  
31  
32  
33 31. Faculty of Pain Medicine of Royal College of Anaesthetists. Dose equivalents and  
34 changing opioids [Internet]. London: Faculty of Pain Medicine of Royal College of  
35 Anaesthetists. Available from: [https://fpm.ac.uk/opioids-aware-structured-approach-opioid-](https://fpm.ac.uk/opioids-aware-structured-approach-opioid-prescribing/dose-equivalents-and-changing-opioids)  
36 [prescribing/dose-equivalents-and-changing-opioids](https://fpm.ac.uk/opioids-aware-structured-approach-opioid-prescribing/dose-equivalents-and-changing-opioids)  
37  
38  
39  
40  
41  
42  
43  
44  
45 32. Sandhu HK, Abraham C, Alleyne S, Balasubramanian S, Betteley L, Booth K, Carnes D,  
46 Furlan AD, Haywood K, Urrutia CP, Lall R. Testing a support programme for opioid  
47 reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled  
48 trial protocol. *BMJ open*. 2019 Aug 1;9(8):e028937.  
49  
50  
51  
52  
53  
54  
55  
56 33. Kolb DA. Experience as the source of learning and development. Upper Sadle River:  
57 Prentice Hall. 1984.  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Figure 1: Stages of I-WOTCH intervention development

**Legend:**

COPERS - coping with persistent pain, effectiveness research into self-management (13)

I-WOTCH- Improving the Wellbeing of Opioid Treated Chronic Pain

NIHR – National Institute of Health Research

PPI - Patient and Public Involvement

RCT – Randomised Controlled Trial

Figure 2: Reducing Opioids for people with chronic non malignant pain






Figure 3: Final model of I-WOTCH intervention

